WO2010151736A1 - Chimeric factor vii molecules - Google Patents
Chimeric factor vii molecules Download PDFInfo
- Publication number
- WO2010151736A1 WO2010151736A1 PCT/US2010/039934 US2010039934W WO2010151736A1 WO 2010151736 A1 WO2010151736 A1 WO 2010151736A1 US 2010039934 W US2010039934 W US 2010039934W WO 2010151736 A1 WO2010151736 A1 WO 2010151736A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- factor
- domain
- chimeric
- protein
- egf
- Prior art date
Links
- 229940012413 factor vii Drugs 0.000 title claims abstract description 176
- 108010023321 Factor VII Proteins 0.000 claims abstract description 182
- 102100023804 Coagulation factor VII Human genes 0.000 claims abstract description 179
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 152
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 147
- 229920001184 polypeptide Polymers 0.000 claims abstract description 145
- 238000000034 method Methods 0.000 claims abstract description 71
- 108090000623 proteins and genes Proteins 0.000 claims description 117
- 102000004169 proteins and genes Human genes 0.000 claims description 77
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 75
- 239000013598 vector Substances 0.000 claims description 55
- 108010076282 Factor IX Proteins 0.000 claims description 54
- 229960004222 factor ix Drugs 0.000 claims description 52
- 208000032843 Hemorrhage Diseases 0.000 claims description 50
- 208000034158 bleeding Diseases 0.000 claims description 50
- 230000000740 bleeding effect Effects 0.000 claims description 50
- 108020001778 catalytic domains Proteins 0.000 claims description 33
- 108010066124 Protein S Proteins 0.000 claims description 31
- 229940096437 Protein S Drugs 0.000 claims description 31
- 150000007523 nucleic acids Chemical class 0.000 claims description 27
- 208000031169 hemorrhagic disease Diseases 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 230000015271 coagulation Effects 0.000 claims description 23
- 238000005345 coagulation Methods 0.000 claims description 23
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 19
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 19
- 239000003114 blood coagulation factor Substances 0.000 claims description 19
- 208000009292 Hemophilia A Diseases 0.000 claims description 17
- 208000014674 injury Diseases 0.000 claims description 17
- 230000002950 deficient Effects 0.000 claims description 16
- 208000031220 Hemophilia Diseases 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 230000007812 deficiency Effects 0.000 claims description 12
- 230000003197 catalytic effect Effects 0.000 claims description 10
- 238000001356 surgical procedure Methods 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 9
- 230000008733 trauma Effects 0.000 claims description 9
- 229930003448 Vitamin K Natural products 0.000 claims description 8
- 230000001419 dependent effect Effects 0.000 claims description 8
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 8
- 235000019168 vitamin K Nutrition 0.000 claims description 8
- 239000011712 vitamin K Substances 0.000 claims description 8
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 8
- 229940046010 vitamin k Drugs 0.000 claims description 8
- 208000027276 Von Willebrand disease Diseases 0.000 claims description 6
- 206010043554 thrombocytopenia Diseases 0.000 claims description 6
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 claims description 6
- 102100028885 Vitamin K-dependent protein S Human genes 0.000 claims 6
- 230000005764 inhibitory process Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 83
- 235000018102 proteins Nutrition 0.000 description 67
- 125000003275 alpha amino acid group Chemical group 0.000 description 62
- 241000699666 Mus <mouse, genus> Species 0.000 description 60
- 231100000319 bleeding Toxicity 0.000 description 48
- 125000000539 amino acid group Chemical group 0.000 description 39
- 108020004414 DNA Proteins 0.000 description 26
- 102000029301 Protein S Human genes 0.000 description 25
- 108090000190 Thrombin Proteins 0.000 description 25
- 229960004072 thrombin Drugs 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 23
- 208000009429 hemophilia B Diseases 0.000 description 22
- 239000012634 fragment Substances 0.000 description 21
- 238000006467 substitution reaction Methods 0.000 description 20
- 108010000499 Thromboplastin Proteins 0.000 description 19
- 102000002262 Thromboplastin Human genes 0.000 description 19
- 238000001415 gene therapy Methods 0.000 description 19
- 238000011282 treatment Methods 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 16
- 230000023597 hemostasis Effects 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 229940099816 human factor vii Drugs 0.000 description 15
- 108010013773 recombinant FVIIa Proteins 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 14
- 238000005516 engineering process Methods 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 150000003904 phospholipids Chemical class 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 12
- 230000008488 polyadenylation Effects 0.000 description 12
- 239000013615 primer Substances 0.000 description 12
- 239000013603 viral vector Substances 0.000 description 12
- 101100226845 Strongylocentrotus purpuratus EGF2 gene Proteins 0.000 description 11
- 208000007536 Thrombosis Diseases 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 108010060630 Lactoglobulins Proteins 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 235000013336 milk Nutrition 0.000 description 10
- 239000008267 milk Substances 0.000 description 10
- 210000004080 milk Anatomy 0.000 description 10
- 230000009261 transgenic effect Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 229940030225 antihemorrhagics Drugs 0.000 description 9
- 230000035602 clotting Effects 0.000 description 9
- 230000000025 haemostatic effect Effects 0.000 description 9
- 210000004962 mammalian cell Anatomy 0.000 description 9
- 229940112216 novoseven Drugs 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 210000001082 somatic cell Anatomy 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 230000004988 N-glycosylation Effects 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 108010011756 Milk Proteins Proteins 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108010074860 Factor Xa Proteins 0.000 description 6
- -1 a-lactalbumin Proteins 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 229940127219 anticoagulant drug Drugs 0.000 description 6
- 125000002091 cationic group Chemical group 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 102000004506 Blood Proteins Human genes 0.000 description 5
- 108010017384 Blood Proteins Proteins 0.000 description 5
- 206010053567 Coagulopathies Diseases 0.000 description 5
- 108010062466 Enzyme Precursors Proteins 0.000 description 5
- 102000010911 Enzyme Precursors Human genes 0.000 description 5
- 108010014173 Factor X Proteins 0.000 description 5
- 108091092195 Intron Proteins 0.000 description 5
- 102000008192 Lactoglobulins Human genes 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000023555 blood coagulation Effects 0.000 description 5
- 239000000701 coagulant Substances 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940012426 factor x Drugs 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000004481 post-translational protein modification Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- 102100026735 Coagulation factor VIII Human genes 0.000 description 4
- 241000702421 Dependoparvovirus Species 0.000 description 4
- 102000012545 EGF-like domains Human genes 0.000 description 4
- 108050002150 EGF-like domains Proteins 0.000 description 4
- 201000003542 Factor VIII deficiency Diseases 0.000 description 4
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 102000014171 Milk Proteins Human genes 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 235000021239 milk protein Nutrition 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 230000000451 tissue damage Effects 0.000 description 4
- 231100000827 tissue damage Toxicity 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229940122295 Clotting factor inhibitor Drugs 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 108010048049 Factor IXa Proteins 0.000 description 3
- 102000001690 Factor VIII Human genes 0.000 description 3
- 108010054218 Factor VIII Proteins 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 206010017866 Gastritis haemorrhagic Diseases 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Natural products SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
- 108010094028 Prothrombin Proteins 0.000 description 3
- 102100027378 Prothrombin Human genes 0.000 description 3
- 108020005067 RNA Splice Sites Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 108010022999 Serine Proteases Proteins 0.000 description 3
- 102000012479 Serine Proteases Human genes 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 206010046788 Uterine haemorrhage Diseases 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 210000003027 ear inner Anatomy 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960000301 factor viii Drugs 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002357 laparoscopic surgery Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 150000002634 lipophilic molecules Chemical class 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229940039716 prothrombin Drugs 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- 102100036537 von Willebrand factor Human genes 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 108020005029 5' Flanking Region Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 229920002491 Diethylaminoethyl-dextran Polymers 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000701109 Human adenovirus 2 Species 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 2
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 102000017975 Protein C Human genes 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 108091005605 Vitamin K-dependent proteins Proteins 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000004671 cell-free system Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000006251 gamma-carboxylation Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000010005 growth-factor like effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940019333 vitamin k antagonists Drugs 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- 229960005080 warfarin Drugs 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CWGBFIRHYJNILV-UHFFFAOYSA-N (1,4-diphenyl-1,2,4-triazol-4-ium-3-yl)-phenylazanide Chemical compound C=1C=CC=CC=1[N-]C1=NN(C=2C=CC=CC=2)C=[N+]1C1=CC=CC=C1 CWGBFIRHYJNILV-UHFFFAOYSA-N 0.000 description 1
- GLAYWTQUVABFHB-RUCXOUQFSA-N (3s)-3-aminopropane-1,1,3-tricarboxylic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O.OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O GLAYWTQUVABFHB-RUCXOUQFSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 1
- NEWKHUASLBMWRE-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine Chemical compound CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 NEWKHUASLBMWRE-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101800001401 Activation peptide Proteins 0.000 description 1
- 102400000069 Activation peptide Human genes 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 229940122601 Esterase inhibitor Drugs 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 108010071241 Factor XIIa Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001049020 Homo sapiens Coagulation factor VII Proteins 0.000 description 1
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical group OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 101100084430 Mus musculus Pros1 gene Proteins 0.000 description 1
- 101000635833 Mus musculus Tissue factor Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- ATHGHQPFGPMSJY-UHFFFAOYSA-N Spermidine Natural products NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102000012349 Uroplakins Human genes 0.000 description 1
- 108010061861 Uroplakins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 101710087237 Whey acidic protein Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229940006612 barium citrate Drugs 0.000 description 1
- PAVWOHWZXOQYDB-UHFFFAOYSA-H barium(2+);2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ba+2].[Ba+2].[Ba+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PAVWOHWZXOQYDB-UHFFFAOYSA-H 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 229940105772 coagulation factor vii Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940012414 factor viia Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- KLHSDMQFUVANEB-MELZOAELSA-L hexadecyl-[(2r,3r)-4-[hexadecyl(dimethyl)azaniumyl]-2,3-dimethoxybutyl]-dimethylazanium;dibromide Chemical compound [Br-].[Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C[C@@H](OC)[C@H](OC)C[N+](C)(C)CCCCCCCCCCCCCCCC KLHSDMQFUVANEB-MELZOAELSA-L 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960000027 human factor ix Drugs 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- SQMWSBKSHWARHU-SDBHATRESA-N n6-cyclopentyladenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 SQMWSBKSHWARHU-SDBHATRESA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000011473 radical retropubic prostatectomy Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229940068953 recombinant fviia Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L23/00—Details of semiconductor or other solid state devices
- H01L23/28—Encapsulations, e.g. encapsulating layers, coatings, e.g. for protection
- H01L23/29—Encapsulations, e.g. encapsulating layers, coatings, e.g. for protection characterised by the material, e.g. carbon
- H01L23/291—Oxides or nitrides or carbides, e.g. ceramics, glass
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L23/00—Details of semiconductor or other solid state devices
- H01L23/28—Encapsulations, e.g. encapsulating layers, coatings, e.g. for protection
- H01L23/31—Encapsulations, e.g. encapsulating layers, coatings, e.g. for protection characterised by the arrangement or shape
- H01L23/3157—Partial encapsulation or coating
- H01L23/3171—Partial encapsulation or coating the coating being directly applied to the semiconductor body, e.g. passivation layer
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L29/00—Semiconductor devices specially adapted for rectifying, amplifying, oscillating or switching and having potential barriers; Capacitors or resistors having potential barriers, e.g. a PN-junction depletion layer or carrier concentration layer; Details of semiconductor bodies or of electrodes thereof ; Multistep manufacturing processes therefor
- H01L29/40—Electrodes ; Multistep manufacturing processes therefor
- H01L29/41—Electrodes ; Multistep manufacturing processes therefor characterised by their shape, relative sizes or dispositions
- H01L29/423—Electrodes ; Multistep manufacturing processes therefor characterised by their shape, relative sizes or dispositions not carrying the current to be rectified, amplified or switched
- H01L29/42312—Gate electrodes for field effect devices
- H01L29/42316—Gate electrodes for field effect devices for field-effect transistors
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L29/00—Semiconductor devices specially adapted for rectifying, amplifying, oscillating or switching and having potential barriers; Capacitors or resistors having potential barriers, e.g. a PN-junction depletion layer or carrier concentration layer; Details of semiconductor bodies or of electrodes thereof ; Multistep manufacturing processes therefor
- H01L29/66—Types of semiconductor device ; Multistep manufacturing processes therefor
- H01L29/66007—Multistep manufacturing processes
- H01L29/66075—Multistep manufacturing processes of devices having semiconductor bodies comprising group 14 or group 13/15 materials
- H01L29/66227—Multistep manufacturing processes of devices having semiconductor bodies comprising group 14 or group 13/15 materials the devices being controllable only by the electric current supplied or the electric potential applied, to an electrode which does not carry the current to be rectified, amplified or switched, e.g. three-terminal devices
- H01L29/66409—Unipolar field-effect transistors
- H01L29/66446—Unipolar field-effect transistors with an active layer made of a group 13/15 material, e.g. group 13/15 velocity modulation transistor [VMT], group 13/15 negative resistance FET [NERFET]
- H01L29/66462—Unipolar field-effect transistors with an active layer made of a group 13/15 material, e.g. group 13/15 velocity modulation transistor [VMT], group 13/15 negative resistance FET [NERFET] with a heterojunction interface channel or gate, e.g. HFET, HIGFET, SISFET, HJFET, HEMT
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L29/00—Semiconductor devices specially adapted for rectifying, amplifying, oscillating or switching and having potential barriers; Capacitors or resistors having potential barriers, e.g. a PN-junction depletion layer or carrier concentration layer; Details of semiconductor bodies or of electrodes thereof ; Multistep manufacturing processes therefor
- H01L29/66—Types of semiconductor device ; Multistep manufacturing processes therefor
- H01L29/68—Types of semiconductor device ; Multistep manufacturing processes therefor controllable by only the electric current supplied, or only the electric potential applied, to an electrode which does not carry the current to be rectified, amplified or switched
- H01L29/76—Unipolar devices, e.g. field effect transistors
- H01L29/772—Field effect transistors
- H01L29/778—Field effect transistors with two-dimensional charge carrier gas channel, e.g. HEMT ; with two-dimensional charge-carrier layer formed at a heterojunction interface
- H01L29/7786—Field effect transistors with two-dimensional charge carrier gas channel, e.g. HEMT ; with two-dimensional charge-carrier layer formed at a heterojunction interface with direct single heterostructure, i.e. with wide bandgap layer formed on top of active layer, e.g. direct single heterostructure MIS-like HEMT
- H01L29/7787—Field effect transistors with two-dimensional charge carrier gas channel, e.g. HEMT ; with two-dimensional charge-carrier layer formed at a heterojunction interface with direct single heterostructure, i.e. with wide bandgap layer formed on top of active layer, e.g. direct single heterostructure MIS-like HEMT with wide bandgap charge-carrier supplying layer, e.g. direct single heterostructure MODFET
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L29/00—Semiconductor devices specially adapted for rectifying, amplifying, oscillating or switching and having potential barriers; Capacitors or resistors having potential barriers, e.g. a PN-junction depletion layer or carrier concentration layer; Details of semiconductor bodies or of electrodes thereof ; Multistep manufacturing processes therefor
- H01L29/02—Semiconductor bodies ; Multistep manufacturing processes therefor
- H01L29/12—Semiconductor bodies ; Multistep manufacturing processes therefor characterised by the materials of which they are formed
- H01L29/20—Semiconductor bodies ; Multistep manufacturing processes therefor characterised by the materials of which they are formed including, apart from doping materials or other impurities, only AIIIBV compounds
- H01L29/2003—Nitride compounds
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
- H01L2924/0001—Technical content checked by a classifier
- H01L2924/0002—Not covered by any one of groups H01L24/00, H01L24/00 and H01L2224/00
Definitions
- the present invention relates to chimeric human coagulation Factor VII (FVII) polypeptides having greater coagulant activity and fewer thrombotic complications than presently available Factor VII polypeptides, as well as polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing the polynucleotides, pharmaceutical compositions, uses and methods of treatment.
- FVII human coagulation Factor VII
- Blood coagulation is a process consisting of a complex interaction of various blood components (or factors) that eventually gives rise to a fibrin clot.
- the blood components which participate in what has been referred to as the coagulation "cascade,” are enzymatically inactive proteins (proenzymes or zymogens) that are converted to proteolytic enzymes by the action of an activator (which itself is an activated clotting factor).
- Coagulation factors that have undergone such a conversion are generally referred to as "active factors,” and are designated by the addition of the letter “a” to the name of the coagulation factor (e.g., activated Factor VII is designated as Factor Vila or FVIIa).
- active factors e.g., activated Factor VII is designated as Factor Vila or FVIIa.
- initiation of the haemostatic process is mediated by the formation of a complex between tissue factor and Factor Vila.
- This complex then converts Factors IX (FIX) and X (FX) to their active forms.
- Factor Xa (FXa) converts limited amounts of prothrombin to thrombin on the tissue factor-bearing cell.
- Thrombin activates platelets and Factors V (FV) and VIII (FVIII) into Factors Va (FVa) and Villa (FVIIIa), both cofactors in the further process leading to the full thrombin burst.
- This process includes generation of Factor Xa by Factor IXa (FIXa) (in complex with Factor Villa) and occurs on the surface of activated platelets. Thrombin finally converts fibrinogen to fibrin resulting in formation of a fibrin clot, hi recent years Factor VII and tissue factor have been found to be the main initiators of blood coagulation.
- FIXa Factor IXa
- Factor VII is a plasma glycoprotein that circulates in blood as a single-chain zymogen.
- the zymogen has marginal catalytic activity.
- Single-chain Factor VII may be converted to two-chain Factor Vila by Factor Xa, Factor XIIa, Factor IXa, Factor Vila or thrombin in vitro.
- Factor Xa is believed to be the major physiological activator of Factor VII.
- Factor VII is dependent on Vitamin K for its activity, which is required for the gamma-carboxylation of multiple glutamic acid residues that are clustered close to the amino terminus of the protein.
- hFVII human FVII
- FVII The gene organization and protein structure of FVII are similar to those of other vitamin K-dependent procoagulant proteins, with exons Ia and Ib encoding for signal sequence; exon 2 the propeptide and GLA domain; exon 3 a short hydrophobic region; exons 4 and 5 the epidermal growth factor-like domains; and exon 6 through 8 the serine protease catalytic domain (Yoshitake et al., Biochemistry 1985; 24: 3736-3750).
- Factor IX (Christmas factor) is the zymogen of a serine protease active in normal hemostasis and the enzymatic activity requires carboxylation of specific glutamic acid residues.
- Factors IX, X, VII and protein C are closely related paralogs of the same family of serine proteases, with a high degree of amino acid sequence identity and intron-exon arrangement of the genes coding for these proteins. These closely related proteins have a similar structure of functional domains from the amino to carboxyl terminus to include a ⁇ - carboxyglutamic acid (GLA) domain, two epidermal growth factor-like (EGF) domains, an activation peptide and the catalytic domain.
- GLA ⁇ - carboxyglutamic acid
- EGF epidermal growth factor-like
- Protein S is a 666 amino acid, vitamin K- dependent protein with a GLA domain, 4 EGF-like domains, a thrombin sensitive region and 2 laminin domains.
- the vitamin K dependent coagulation plasma proteins contain a GLA domain that functions as the site of protein attachment to membranes and the GLA domain is highly conserved among the various coagulation proteins. Despite their similarity, the GLA domains exhibit a wide range of affinities for phospholipid, with the GLA domain of Protein S having the highest affinity for phospholipids. (Ellison et al., Biochemistry, 1998; 37:7997- 8003), (McDonald et al., Biochemistry 1997; 36:5120-27).
- Factor Vila has been used to control bleeding disorders that have several causes such as clotting factor deficiencies (e.g., hemophilia A and B or deficiency of coagulation Factors XI or VII) or clotting factor inhibitors.
- Factor Vila has also been used to control excessive bleeding occurring in subjects with a normally functioning blood clotting cascade (no clotting factor deficiencies or inhibitors against any of the coagulation factors). Such bleeding may, for example, be caused by a defective platelet function, thrombocytopenia or von Willebrand's disease.
- Warnings relating to treatment with Factor VII are currently proposed for products seeking regulatory approval.
- the European Medicines Agency, Human Medicines Evaluation Unit recommends that current Factor VII therapies carry a warning of the risk of thrombosis and disseminated intravascular coagulation, particularly in situations where the Factor VII is to be administered to patients with a history of coronary heart disease or liver disease, post-operative patients, neonates and those at risk from thrombosis and disseminated intravascular coagulation. See, e.g., Core SPC for Human Plasma Derived Coagulation Factor VII Products (CPMP/BPWG/2048/01), July, 2004.
- NovoSeven ® and NovoSeven ® RT are indicated for the treatment of bleeding episodes in hemophilia A or B patients and are the only rFVIIa for treatment of bleeding episodes available on the market.
- NovoSeven® may bind to rehydrated lyophilized platelets, which could be administered in combination to localize the Factor VII to a site of injury. (Fischer et al., Platelets, 2008; 19:182-91). Additionally, it has been shown that selective PEGylation of Factor VII may increase plasma half-life, (Stennicke et al., Thromb.
- chimeric FVIIa molecules in particular chimeric hFVIIa molecules comprising hFVIIa domains and domains from one or more proteins of the coagulation system, providing one or more desired benefits.
- the chimeric FVIIa molecules of the present invention therefore, have one or more improved properties as compared to commercially available rFVIIa, including having higher coagulant activity and/or being able to be administered at relatively low doses and/or producing fewer thrombotic complications. Consequently, medical treatment with a chimera of the invention offers advantages over the currently available rFVIIa compound, such as potentially lower doses and/or fewer undesirable side effects.
- Representative chimeric FVIIa polypeptides of the invention include a chimeric FVIIa comprising the EGF-2 and catalytic domains of FVII and the GLA domain of a vitamin K- dependent coagulation protein and the EGF-I domain of a vitamin K-dependent coagulation protein.
- chimeric FVIIa polypeptides of the invention include 1) a chimeric FVIIa comprising the GLA and EGF-I domains of FIX and the EGF-2 and catalytic domains of FVII; 2) a chimeric FVIIa comprising the EGF-I domain of FIX and the GLA, EGF-2 and catalytic domains of FVII; 3) a chimeric FVIIA comprising the GLA domain of Protein S, the EGF-I domain of FIX and the EGF-2 and catalytic domains of FVII; 4) a chimeric FVIIa comprising the GLA and EGF-I domains of Protein S and the EGF-2 and catalytic domains of FVII; 5) a chimeric FVIIa comprising the EGF-I domain of Protein S and the GLA, EGF-2 and catalytic domains of FVII; and 6) a chimeric FVIIa comprising the EGF-I domain of Protein S and the G
- Representative chimeric FVIIa polypeptides of the invention also may include wild-type FVIIa or any of the above described chimeric FVIIa polypeptides, which have amino acid substitutions in the EGF-I domain or the GLA domain.
- the substitutions can be conservative substitutions or non-conservative substitutions.
- Such substitutions may include the substitution of the isoleucine at residue 69 by alanine and/or a substitution of the arginine at residue 79 by alanine of the EGF-I domain.
- Additional substitutions may include the substitution of the lysine at residue 5 by arginine, which causes the GLA domain to have a higher binding affinity for collagen type IV but does not appear to affect platelet binding (Gui et al, J.
- the method of treating the bleeding disorder may include a method of administering to the subject a nucleic acid molecule comprising a nucleotide sequence encoding a chimeric Factor Vila polypeptide of this invention.
- the invention provides a method of treating a bleeding disorder in a subject having the bleeding disorder by administering a protein comprising a GLA domain, wherein the protein is targeted to and/or concentrated near the site of a clot in relation to the concentration of the protein in circulation in the subject's plasma.
- a protein comprising a GLA domain
- This may include using domains that bind with greater affinity to platelets, which are found at or near the site of clot formation, than the currently available Factor VII polypeptides. Examples of such domains are the GLA domains of various coagulation proteins that bind the negatively charged phospholipid layers located on the surface of platelets.
- GLA domains include the GLA domain of FIX, which binds much tighter than the GLA domain of FVIIa to platelets and phospholipids (Melton et al. "Location of the platelet binding site in zymogen coagulation factor IX” Blood Coagul Fibrinolysis 12:237-243 (2001)) and the GLA domain of protein S, which binds phospholipids tighter than any other known GLA domain (McDonald et al. "Comparison of naturally occurring vitamin K-dependent proteins: correlation of amino acid sequences and membrane binding properties suggests a membrane contact site” Biochemistry:36:5120-5121 (1997)).
- Nonlimiting examples of a protein comprising a GLA domain include a recombinant protein comprising a GLA domain of FIX or Protein S, a chimeric protein comprising a GLA domain of FIX or Protein S and/or a chimeric FVIIa polypeptide of this invention comprising a GLA domain of FIX or Protein S.
- the present invention provides a method of treating a subject having a bleeding disorder by administering a chimeric Factor Vila polypeptide of the invention that comprises a catalytic domain derived from a Factor VII polypeptide and a platelet targeting domain, or domains.
- platelet targeting domains include domains from proteins that interact or bind to the surface of a platelet.
- Such interaction or binding to the surface of a platelet can be mediated through the membrane phospholipids of the platelet, or through platelet cell surface proteins and/or receptors.
- Nonlimiting examples of such domains include the Al domain of von Willebrand Factor, which is the principal binding site for platelet glycoprotein Ib (Emsley et al., JBC, 273:10396-10401 (1998)) and the Fab fragment (domain) of antibodies that binds to platelet membrane proteins and/or receptors, such as an antibody that binds to platelet membrane phospholipids (Out et al., Blood, 77:2655-2659 (1991)).
- Such targeting of coagulation proteins to the site of a clot using a domain that binds to platelets and has reduced affinity for tissue factor has the additional, but unexpected benefit of decreasing the risk of complications associated with current Factor VII therapies, such as thrombogenicity.
- This approach can also be used to target other therapeutically useful polypeptides or other molecules to platelets, or the site of a clot.
- therapeutically useful molecules may include anti-coagulants and the like.
- the present invention further provides a method of treating a bleeding disorder in a subject having the bleeding disorder by administering to the subject a polypeptide with reduced thrombogenicity in relation to the thrombogenicity of Factor VII (e.g., reduced at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, etc. in relation to the thrombogenicity of native Factor VII).
- a polypeptide with reduced thrombogenicity in relation to the thrombogenicity of Factor VII e.g., reduced at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, etc. in relation to the
- Reduced thrombogenicity can be determined in a variety of ways according to art-known methods, including but not limited to a determination of a reduced number of clots, smaller clots, longer time required for clots to occur ⁇ in vivo or in an in vitro assay, fewer subject deaths due to thrombus formation and/or extended survival time, as compared to control.
- a polypeptide with reduced thrombogenicity as compared with Factor VII can be, for example, a chimeric Factor VII polypeptide of this invention or active fragment thereof.
- Nonlimiting examples of such polypeptides include a chimeric FVIIa comprising the GLA and EGF-I domains of FIX and the EGF-2 and catalytic domains of FVII and a chimeric FVIIa comprising the GLA domain of Protein S, the EGF-I domain of FIX and the EGF-2 and catalytic domains of FVII.
- FIG. 1 shows a diagrammatic representation of chimeric FVIIa molecules useful in the present invention.
- FVII Factor VII
- FIX Factor IX
- FIG. 2 shows the thrombin generation (nM) in normal conditions and hemophilic conditions (removal of Factor IX and Factor VIII) in a cell based model system of hemophilia for varying concentrations of wild-type Factor Vila.
- FIG. 3 shows the thrombin generation (nM) in normal conditions and hemophilic conditions (removal of Factor IX and Factor VIII) in a cell based model system of hemophilia with administration of 5OnM wild-type Factor Vila, or 1OnM chimeric Factor Vila.
- FIG. 4 shows the peak thrombin, relative to the control value, produced in a cell based model system of hemophilia following administration of 5OnM wild-type Factor Vila, or 1OnM chimeric Factor Vila.
- FIG. 5 shows the disruption hemostasis time in a clotting assay for a hemophilia B mouse with no treatment, a hemophilia B mouse administered with 2mg/kg of NovoSeven®, a hemophilia B mouse administered with 2mg/kg of a chimeric FVIIa molecule and a wild- type mouse with no treatment.
- FIG. 6 shows the sequence of an exemplary chimeric Factor VII of the present invention, comprising the signal, pro peptide, GLA and EGFl domains of Factor IX (underlined) (SEQ ID NO:1).
- FIG. 7 shows the sequence of an exemplary chimeric Factor VII of the present invention, comprising the signal, pro peptide, and EGFl domains of Factor IX (underlined), and the GLA domain of Protein S (bold) (SEQ ID NO: 2).
- any feature or combination of features set forth herein can be excluded or omitted.
- any feature or combination of features set forth herein can be excluded or omitted.
- activity means the ability of a Factor VII polypeptide to convert its substrate Factor X to the active Factor Xa.
- inherent activity also includes the ability to generate thrombin on the surface of activated platelets in the absence of tissue factor.
- N-terminal GLA-domain includes the amino acid sequence from about amino acid residue 61 to about amino acid residue 105 of the amino acid sequence SEQ ID NO: 18), the amino acid sequence from about amino acid residue 47 to about amino acid residue 92 of the amino acid sequence of SEQ ID NO: 19, any post-translational modifications to the identified amino acid sequences, any conservative amino acid substitutions in the identified amino acid sequences, addition of amino acid residues to the identified amino acid sequences, deletions of amino acid residues from the identified amino acid sequences, or any other amino acid sequence from a coagulation cascade protein that binds to phospholipid membranes.
- EGF-I describes a region of 30-40 amino acids containing six cysteines found originally in EGF (epidermal growth factor) and also in a range of proteins involved in cell signaling and in coagulation proteins, with nearly all known EGF-like domains containing disulfide bonds 1-3, 2-4 and 5-6.
- the EGF-I domain of Factor VII is from about amino acid residue 106 to about amino acid residue 142 of the amino acid sequence of SEQ ID NO:18.
- the EGF-I domain of Factor IX is from about amino acid residue 93 to about amino acid residue 129 of the amino acid sequence of SEQ ID NO:19.
- the EGF-I domain of Protein S is from about amino acid residue 117 to about amino acid residue 155 of the amino acid sequence of SEQ ID NO:20. These amino acid sequences can include any post-translational modifications to the identified amino acid sequences, any conservative amino acid substitutions in the identified amino acid sequences, any addition of amino acid residues to the identified amino acid sequences and/or any deletions of amino acid residues from the identified amino acid sequences.
- the term "EGF-2" means the second EGF-like domain in a series (of two or more
- the EGF-2 domain of Factor VII is from about amino acid residue 147 to about amino acid residue 188 in the amino acid sequence of SEQ ID NO: 18.
- the EGF-2 domain of Factor IX is from about amino acid residue 130 to about amino acid residue 171 in the amino acid sequence of SEQ ID NO: 19.
- the EGF-2 domain of Protein S is from about amino acid residue 157 to about amino acid residue 200 in the amino acid sequence of SEQ ID NO:20.
- catalytic domain as used herein means a domain in a protein that mediates cleavage of peptide bonds.
- the catalytic domain of Factor VII is from about amino acid residue 213 to about amino acid residue 452 in the amino acid sequence of SEQ ID NO: 18.
- the catalytic domain of Factor IX is from about amino acid residue 227 to about amino acid residue 459 in the amino acid sequence of SEQ ID NO: 19.
- These amino acid sequences can include any post-translational modifications to the identified amino acid sequences, any conservative amino acid substitutions in the identified amino acid sequences, any addition of amino acid residues to the identified amino acid sequences and/or any deletions of amino acid residues from the identified amino acid sequences.
- GLA 4-carboxyglutamic acid ( ⁇ - carboxyglutamate) .
- proteease domain means a domain in a protein that mediates cleavage of peptide bonds, generally considered to be from about amino acid residue 213 to the carboxy terminal amino acid residue of SEQ ID NO: 18. (the heavy-chain of Factor Vila).
- Factor VII polypeptide as used herein means any protein comprising the amino acid sequence 61-466 of native human Factor VII (SEQ ID NO: 18) or variants or fragments thereof. This includes but is not limited to human Factor VII, human Factor Vila and variants thereof.
- the term “Factor VII” as used herein is intended to comprise the inactive one-chain zymogen Factor VII molecule as well as the activated two-chain Factor VII molecule (Factor Vila).
- proteins that have the amino acid sequence 61-466 (SEQ ID NO: 18) of native human Factor VII or Factor Vila One of skill in the art recognizes that minor sequence changes would be expected to perform in a similar manner and that the domains, polypeptides and Factor VII involved could be slightly shortened or lengthened or contain substitutions without departing from the invention.
- the definition also encompasses proteins and peptides with a slightly modified amino acid sequence, for instance, a modified N-terminal end including N-terminal amino acid deletions or additions such that in some embodiments those proteins substantially retain the activity of Factor Vila (e.g., retain about 50%, 60%, 70%, 80%, 90%, 95%, etc. of the activity of native Factor Vila).
- Factor Vila or “FVIIa” as used herein means a product consisting of the activated form (Factor Vila).
- Factor VII or “Factor Vila” within the above definition also includes natural allelic variations that may exist and occur from one individual to another. Also, degree and location of glycosylation or other post- translation modifications may vary depending on the chosen host cells, tissue, or animal species of expression and the nature of the host cellular, or tissue environment.
- domain as used herein is intended to encompass a part of a protein sequence and structure that can evolve, function, and exist independently of the rest of the protein chain.
- a domain is capable of forming a compact three-dimensional structure and often can be independently stable and folded.
- One domain may appear in a variety of evolutionarily related proteins. Domains vary in length from between about 25 amino acids up to about 500 amino acids in length.
- a "domain” can also encompass a domain from a wild-type protein that has had an amino acid residue, or residues, replaced by conservative substitution. Because they are self-stable in a protein milieu, domains can be "swapped" by genetic engineering between one protein and another to make chimeric proteins.
- variant or “variants,” as used herein, is intended to designate Factor VII having the amino acid sequence 61-466 (SEQ ID NO: 18) of native human Factor VII or Factor Vila, wherein one or more amino acids of the parent protein have been substituted by another amino acid and/or wherein one or more amino acids of the parent protein have been deleted and/or wherein one or more amino acids have been inserted in protein and/or wherein one or more amino acids have been added to the parent protein and/or wherein the GLA domain has been substituted with a GLA domain from a different protein (e.g., a GLA domain that binds to platelet membranes or phospholipid membranes) and/or wherein the GLA domain has been substituted with a platelet-binding domain from a different protein (e.g., the Al domain of von Willebrand Factor, which is the principal binding site for platelet glycoprotein Ib (Emsley et al., JBC, 273:10396-10401 (1998)) and the
- the "variant" or “variants” of this invention can still have FVII clotting activity in their activated form. In some embodiments, the variant or variants of this invention may not have clotting activity.
- a variant is at least, 40%, 50%, 60% or 70% identical with the amino acid sequence 61-466 (SEQ ID NO:18) of native human Factor VII or Factor Vila.
- the EGF-I domain of FVII has 65.7% identity with the EGF-I domain of FIX and the GLA domain of FVII has 58.6% identity with the GLA domain of FIX and 51% identity with the GLA domain of Protein S.
- a variant is at least 80% identical with the amino acid sequence 61-466 (SEQ ID NO: 18) of native human Factor VII or Factor Vila.
- a variant is at least 90% identical with the amino acid sequence 61-466 (SEQ ID NO: 18) of native human Factor VII or Factor Vila. In a further embodiment a variant is at least 95% identical with the amino acid sequence 61-466 (SEQ ID NO: 18) of native human Factor VII or Factor Vila.
- any other amino acid means one amino acid that is different from that amino acid naturally present at that position. This includes but is not limited to amino acids that can be encoded by a polynucleotide. Preferably the different amino acid is in natural L-form and can be encoded by a polynucleotide. A specific example is L-cysteine (Cys).
- operably linked refers to the covalent joining of two or more nucleotide sequences, by means of enzymatic ligation or otherwise, in a configuration relative to one another such that the normal function of the sequences can be performed.
- the nucleotide sequence encoding a presequence or secretory leader is operably linked to a nucleotide sequence coding for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide: a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence of interest; a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation into the protein or peptide of interest.
- "operably linked" means that the nucleotide sequences being linked are contiguous and in the case of a secretory leader, contiguous and in reading phase. Linking is most easily accomplished by ligation at convenient restriction sites. If such sites do not exist, then synthetic oligonucleotide adaptors or linkers are used, in conjunction with standard recombinant DNA methods.
- vector means any nucleic acid entity capable of amplification in a host cell.
- the vector may be an autonomously replicating vector, i.e., a vector, which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid.
- the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated. The choice of vector will often depend on the host cell into which it is to be introduced.
- Vectors include, but are not limited to plasmid vectors, phage vectors, viruses or cosmid vectors. Vectors usually contain a replication origin and at least one selectable gene, i.e., a gene which encodes a product which is readily detectable or the presence of which is essential for cell growth.
- host cell represents any cell, including hybrid cells, in which heterologous DNA can be expressed.
- Typical host cells include, but are not limited to insect cells, yeast cells, mammalian cells, including human cells, such as BHK, CHO, HEK, and COS cells.
- the host cells being cultivated are preferably mammalian cells, more preferably an established mammalian cell line, including, without limitation, CHO (e.g., ATCC CCL 61), COS-I (e.g., ATCC CRL 1650), baby hamster kidney (BHK) and HEK293 (e.g., ATCC CRL 1573; Graham et al., J. Gen. Virol.
- a suitable BHK cell line is the tk " tsl3 BHK cell line (Waechter and Baserga, Proc. Natl. Acad. Sci. USA 79:1106-1110, 1982), hereinafter referred to as BHK 570 cells.
- the BHK 570 cell line is available from the American Type Culture Collection, 10801 University, Boulevard, Manassas, Va. 20110, under ATCC accession number CRL 10314.
- a tk- tsl3 BHK cell line is also available from the ATCC under accession number CRL 1632.
- Suitable cell lines include, without limitation, Rat Hep I (Rat hepatoma; ATCC CRL 1600), Rat Hep II (Rat hepatoma; ATCC CRL 1548), TCMK (ATCC CCL 139), Human lung (ATCC HB 8065), NCTC 1469 (ATCC CCL 9.1) and DUKX cells (Urlaub and Chasin, Proc. Natl. Acad. Sci. USA 77:4216-4220, 1980). Also useful are 3T3 cells, Namalwa cells, myelomas and fusions of myelomas with other cells. As used herein the term "appropriate growth medium” means a medium containing nutrients and other components required for the growth of cells and the expression of the nucleic acid sequence encoding the Factor VII polypeptide of the invention.
- conjugate is intended to indicate a heterogeneous (in the sense of composite or chimeric) molecule formed by the covalent attachment of one or more polypeptide(s) to one or more non-polypeptide moieties such as polymer molecules, lipophilic compounds, sugar moieties or organic derivatizing agents.
- the conjugate is soluble at relevant concentrations and conditions, i.e., soluble in physiological fluids such as blood.
- conjugated polypeptides of the invention include glycosylated and/or PEGylated polypeptides.
- covalent attachment means that the polypeptide and the non-polypeptide moiety are either directly covalently joined to one another, or else are indirectly covalently joined to one another through an intervening moiety or moieties, such as a bridge, spacer, or linkage moiety or moieties.
- non- conjugated polypeptide can be used to refer to the polypeptide part of the conjugate.
- non-polypeptide moiety means a molecule that is capable of conjugating to an attachment group of the polypeptide of the invention. Suitable examples of such molecules include polymer molecules, sugar moieties, lipophilic compounds, or organic derivatizing agents.
- the non-polypeptide moiety is linked to the polypeptide part of the conjugate through an attachment group of the polypeptide.
- the non-polypeptide moiety can be directly covalently joined to the attachment group or it can be indirectly covalently joined to the attachment group through an intervening moiety or moieties, such as a bridge, spacer, or linkage moiety or moieties.
- the "polymer molecule” is a molecule formed by covalent linkage of two or more monomers, wherein none of the monomers is an amino acid residue, except where the polymer is human albumin or another abundant plasma protein.
- polymer can be used interchangeably with the term “polymer molecule.”
- the term is intended to encompass carbohydrate molecules attached by in vitro glycosylation, i.e., a synthetic glycosylation performed in vitro normally involving covalently linking a carbohydrate molecule to an attachment group of the polypeptide, optionally using a cross-linking agent.
- a carbohydrate molecule attached by in vivo glycosylation, such as N- or O- glycosylation (as further described below) is referred to herein as a "sugar moiety.” Except where the number of non-polypeptide moieties, such as polymer molecule(s) or sugar moieties in the conjugate is expressly indicated every reference to "a non-polypeptide moiety" contained in a conjugate or otherwise used in the present invention shall be a reference to one or more non-polypeptide moieties, such as polymer molecule(s) or sugar moieties.
- attachment group is intended to indicate a functional group of the polypeptide, in particular of an amino acid residue thereof or a carbohydrate moiety, capable of attaching a non-polypeptide moiety such as a polymer molecule, a lipophilic molecule, a sugar moiety or an organic derivatizing agent.
- attachment group is used in an unconventional way to indicate the amino acid residues constituting a N-glycosylation site (with the sequence N-X-S/T/C, wherein X is any amino acid residue except proline, N is asparagine and S/T/C is either serine, threonine or cysteine, preferably serine or threonine, and most preferably threonine).
- N is asparagine
- S/T/C is either serine, threonine or cysteine, preferably serine or threonine, and most preferably threonine.
- amino acid residue comprising an attachment group for the non-polypeptide moiety as used in connection with alterations of the amino acid sequence of the polypeptide of interest is to be understood as meaning that one or more amino acid residues constituting an N-glycosylation site are to be altered in such a manner that either a functional N-glycosylation site is introduced into the amino acid sequence or removed from said sequence.
- the term “treat” or “treatment” is meant to include both control and/or prevention of an expected bleeding, such as in surgery, and regulation of an already occurring bleeding, such as in trauma or in on demand treatment for hemophilia patients, with the purpose of inhibiting or minimizing the bleeding.
- Prophylactic administration of the Factor Vila polypeptide according to the invention is thus included in the term "treatment.”
- bleeding disorder reflects any defect, congenital, acquired or induced, of cellular, physiological, or molecular origin that is manifested in bleedings.
- clotting factor deficiencies e.g., hemophilia A and B or deficiency of coagulation Factors XI or VII
- clotting factor inhibitors e.g., defective platelet function, thrombocytopenia, von Willebrand's disease, or bleeding induced by surgery or trauma.
- Excessive bleedings also occur in subjects with a normally functioning blood clotting cascade (no clotting factor deficiencies or inhibitors against any of the coagulation factors) and may be caused by a defective platelet function, thrombocytopenia or von Willebrand's disease, hi such cases, the bleedings may be likened to those bleedings caused by hemophilia because the haemostatic system, as in hemophilia, lacks or has abnormal essential clotting "compounds" (such as platelets or von Willebrand factor protein), causing major bleedings.
- the normal haemostatic mechanism may be overwhelmed by the demand of immediate hemostasis and they may develop bleeding in spite of a normal haemostatic mechanism.
- Achieving satisfactory hemostasis also is a problem when bleedings occur in organs such as the brain, inner ear region and eyes, with limited possibility for surgical hemostasis.
- organs such as the brain, inner ear region and eyes
- the same problem may arise in the process of taking biopsies from various organs (liver, lung, tumor tissue, gastrointestinal tract) as well as in laparoscopic surgery. Common for all these situations is the difficulty to provide hemostasis by surgical techniques (sutures, clips, etc.), which also is the case when bleeding is diffuse (hemorrhagic gastritis and profuse uterine bleeding).
- Acute and profuse bleedings may also occur in subjects on anticoagulant therapy in whom a defective hemostasis has been induced by the therapy given. Such subjects may need surgical interventions in case the anticoagulant effect has to be counteracted rapidly.
- Radical retropubic prostatectomy is a commonly performed procedure for subjects with localized prostate cancer.
- the operation is frequently complicated by significant and sometimes massive blood loss.
- the considerable blood loss during prostatectomy is mainly related to the complicated anatomical situation, with various densely vascularized sites that are not easily accessible for surgical hemostasis, and which may result in diffuse bleeding from a large area.
- intracerebral hemorrhage is the least treatable form of stroke and is associated with high mortality and hematoma growth in the first few hours following intracerebral hemorrhage. Treatment with rFVIIa can limit the growth of the hematoma, reduce mortality, and improve functional outcomes at 90 days.
- chimeric Factor VII molecules of the present invention can overcome this problem in stroke therapy.
- Another situation that may cause problems in the case of unsatisfactory hemostasis is when subjects with a normal haemostatic mechanism are given anticoagulant therapy to prevent thromboembolic disease.
- anticoagulant therapy may include heparin, other forms of proteoglycans, warfarin or other forms of vitamin K-antagonists as well as aspirin and other platelet aggregation inhibitors.
- the bleeding is associated with hemophilia. In another embodiment, the bleeding is associated with hemophilia with acquired inhibitors. In another embodiment, the bleeding is associated with thrombocytopenia. In another embodiment, the bleeding is associated with von Willebrand's disease. In another embodiment, the bleeding is associated with severe tissue damage. In another embodiment, the bleeding is associated with severe trauma. In another embodiment, the bleeding is associated with surgery. In another embodiment, the bleeding is associated with laparoscopic surgery. In another embodiment, the bleeding is associated with hemorrhagic gastritis. In another embodiment, the bleeding is profuse uterine bleeding. In another embodiment, the bleeding is occurring in organs with a limited possibility for mechanical hemostasis.
- the bleeding is occurring in the brain, inner ear region or eyes. In another embodiment, the bleeding is associated with the process of taking biopsies. In another embodiment, the bleeding is associated with anticoagulant therapy.
- subject as used herein is intended to mean any animal, in particular mammals, such as humans, and may, where appropriate, be used interchangeably with the term "patient.”
- the term "enhancement of the normal haemostatic system” means an improvement of the ability to generate thrombin or to generate a functional clot.
- gene therapy refers to a method of changing the expression of an endogenous gene by exogenous administration of a gene.
- gene therapy also refers to the replacement of defective gene encoding a defective protein, or replacement of a missing gene, by introducing a functional gene corresponding to the defective or missing gene into somatic or stem cells of an individual in need.
- Gene therapy can be accomplished by ex vivo methods, in which differentiated or somatic stem cells are removed from the individual's body followed by the introduction of a normal copy of the defective gene into the explanted cells using a viral vector as the gene delivery vehicle.
- gene therapy also refers to the replacement of a defective gene encoding a defective protein by introducing a polynucleotide that functions substantially the same as the defective gene or protein should function if it were not defective into somatic or stem cells of an individual in need.
- gene therapy is employed in the context of administering to a subject a nucleic acid molecule comprising a nucleotide sequence encoding a chimeric FVII of this invention.
- the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a chimeric FVII protein of this invention.
- a nucleic acid molecule can be present in a nucleic acid construct (e.g., a vector or plasmid).
- a nucleic acid construct can be present in a cell.
- a method of delivering a chimeric FVII protein of this invention to a cell comprising introducing into the cell a nucleic acid molecule comprising a nucleotide sequence encoding the chimeric FVII protein under conditions whereby the nucleotide sequence is expressed to produce the chimeric FVII protein in the cell.
- the cell can be a cell that is introduced into a subject and/or the cell can be a cell already present in the subject.
- the chimeric Factor VII polypeptides described herein may be produced by means of recombinant nucleic acid techniques.
- a cloned wild-type Factor VII nucleic acid sequence is modified to encode the desired protein.
- This modified sequence is then inserted into an expression vector, which is in turn transformed or transfected into host cells.
- Higher eukaryotic cells in particular cultured mammalian cells, are suitable as host cells.
- SEQ ID NO: 19 is provided herein as SEQ ID NO: 19; as are the complete nucleotide and amino acid sequences for Protein S (see Hoskins et al. , Proc. Natl. Acad. ScL U.S.A. 1987; 84:349-353 and GenBank ® Accession Nos. Ml 5036 and AAA36479 and SwissProt Accession No. P07225) and the amino acid sequence is provided herein as SEQ ID NO: 20.
- the complete nucleotide and amino acid sequences for other coagulation proteins are also known and can be viewed using SwissProt or at the NCBI web page.
- the amino acid sequence alterations may be accomplished by a variety of techniques. Modification of the nucleic acid sequence may be by site-specific mutagenesis. Techniques for site-specific mutagenesis are well known in the art and are described in, for example, Zoller and Smith (DNA 3:479-488, 1984) or "Splicing by extension overlap", Horton et al., Gene 11, 1989, pp. 61-68. Thus, using the nucleotide and amino acid sequences of Factor VII, one may introduce the alteration(s) of choice. Likewise, procedures for preparing a DNA construct using polymerase chain reaction using specific primers are well known to persons skilled in the art (see, PCR Protocols, 1990, Academic Press, San Diego, Calif., USA).
- the chimeric Factor VII polypeptides of the present invention may be prepared by introducing unique restriction sites into the nucleotide sequences encoding the various polypeptides, which can be used to isolate fragments of nucleotide sequences that encode entire domains of various polypeptides. Subsequently, these various nucleotide sequences can be recombined to produce the various chimeric Factor VII polypeptides of the present invention.
- unique restriction sites may be introduced into the nucleotide sequences encoding various coagulation proteins so that the GLA, EGF-I, EGF-2 and catalytic domains may be freely interchanged between the various coagulation proteins.
- the EGF-I domain can rotate freely around the EGF-2 domain, (Pike et al. Proc Natl. Acad. ScL 1999; 96:8925- 8930) whereas, the GLA and EGF-I domains may not rotate freely around each other when calcium is present (Sunnerhagen et al. Nature Structural Biology 1995; 2:504-509).
- the GLA and EGF-I domains may be from the same coagulation protein, but from a different protein than the EGF-2 and catalytic domains.
- the chimeric Factor Vila polypeptides of the present invention may therefore, comprise domains from any of the coagulation proteins, provided at least 50% of one domain is a Factor VII domain. Further, the chimeric Factor Vila polypeptides of the present invention may include GLA and EGF-I domains from the same protein, or from different proteins.
- the nucleic acid construct encoding the chimeric Factor VII polypeptides of the invention may suitably be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA sequences coding for all or part of the various polypeptides by hybridization using synthetic oligonucleotide probes in accordance with standard techniques (see, Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd. Ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989).
- the nucleic acid construct encoding the chimeric Factor VII polypeptides may also be prepared synthetically by established standard methods, e.g. the phosphoamidite method described by Beaucage and Caruthers, Tetrahedron Letters 22 (1981), 1859-1869, or the method described by Matthes et al., EMBO Journal 3 (1984), 801-805.
- phosphoamidite method oligonucleotides are synthesized, e.g., in an automatic DNA synthesizer, purified, annealed, ligated and cloned in suitable vectors.
- nucleic acid construct may be of mixed synthetic and genomic, mixed synthetic and cDNA or mixed genomic and cDNA origin prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate), the fragments corresponding to various parts of the entire nucleic acid construct, in accordance with standard techniques.
- DNA sequences for use in producing chimeric Factor VII polypeptides according to the present invention will typically encode a pre-pro polypeptide at the amino-terminus of Factor VII to obtain proper posttranslational processing ⁇ e.g., gamma-carboxylation of glutamic acid residues) and secretion from the host cell.
- the pre-pro polypeptide may be that of Factor VII or another vitamin K-dependent plasma protein, such as Factor IX, Factor X, prothrombin, protein C or protein S.
- additional modifications can be made in the amino acid sequence of the chimeric Factor VII polypeptides where those modifications do not significantly impair the ability of the protein to act as a coagulant.
- Expression vectors for use in expressing Factor Vila variants will comprise a promoter capable of directing the transcription of a cloned gene or cDNA.
- Suitable promoters for use in cultured mammalian cells include viral promoters and cellular promoters.
- Viral promoters include the SV40 promoter (Subramani et al., MoI. Cell. Biol. 1:854-864, 1981) and the CMV promoter (Boshart et al., Cell 41:521-530, 1985).
- a particularly suitable viral promoter is the major late promoter from adenovirus 2 (Kaufman and Sharp, MoI. Cell. Biol. 2:1304-1319, 1982).
- Another particularly preferable promoter is the Chinese Hamster elongation factor- 1- alpha (CHEFl) promoter.
- Cellular promoters include the mouse kappa gene promoter (Bergman et al., Proc. Natl. Acad. Sci. USA 81:7041-7045, 1983) and the mouse V H promoter (Loh et al., Cell 33:85-93, 1983).
- a particularly suitable cellular promoter is the mouse metallothionein-I promoter (Palmiter et al., Science 222:809-814, 1983).
- Expression vectors may also contain a set of RNA splice sites located downstream from the promoter and upstream from the insertion site for the chimeric Factor VII sequence itself.
- RNA splice sites may be obtained from adenovirus and/or immunoglobulin genes.
- a polyadenylation signal located downstream of the insertion site.
- Particularly suitable polyadenylation signals include the early or late polyadenylation signal from SV40 (Kaufman and Sharp), the polyadenylation signal from the adenovirus 5 EIb region, the human growth hormone gene terminator (DeNoto et al. Nucl. Acids Res. 9:3719-3730, 1981) or the polyadenylation signal from the human Factor VII gene or the bovine Factor VII gene.
- the expression vectors may also include a noncoding viral leader sequence, such as the adenovirus 2 tripartite leader, located between the promoter and the RNA splice sites; and enhancer sequences, such as the SV40 enhancer.
- Cloned DNA sequences are introduced into cultured mammalian cells by, for example, calcium phosphate-mediated transfection (Wigler et al., Cell 14:725-732, 1978; Corsaro and Pearson, Somatic Cell Genetics 7:603-616, 1981; Graham and Van der Eb, Virology 52d:456-467, 1973) or electroporation (Neumann et al., EMBO J. 1:841-845, 1982).
- a gene that confers a selectable phenotype is generally introduced into cells along with the gene or cDNA of interest.
- Suitable selectable markers include genes that confer resistance to drugs such as neomycin, hygromycin, and methotrexate.
- the selectable marker may be an amplifiable selectable marker.
- a suitable amplifiable selectable marker is a dihydrofolate reductase (DHFR) sequence.
- Another suitable selectable marker is histidinol. Selectable markers are reviewed by Thilly (Mammalian Cell Technology, Butterworth Publishers, Stoneham, Mass., incorporated herein by reference). The person skilled in the art will easily be able to choose suitable selectable markers. Selectable markers may be introduced into the cell on a separate plasmid at the same time as the gene of interest, or they may be introduced on the same plasmid.
- the selectable marker and the gene of interest may be under the control of different promoters or the same promoter, the latter arrangement producing a dicistronic message.
- Constructs of this type are known in the art (for example, Levinson and Simonsen, U.S. Pat. No. 4,713,339), It may also be advantageous to add additional DNA, known as "carrier DNA,” to the mixture that is introduced into the cells.
- the medium used to culture the cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g., in catalogues of the American Type Culture Collection). The media are prepared using procedures known in the art (see, e.g., references for bacteria and yeast; Bennett, J. W. and LaSure, L., editors, More Gene Manipulations in Fungi, Academic Press, CA, 1991). Growth media generally include a carbon source, a nitrogen source, essential amino acids, essential sugars, vitamins, salts, phospholipids, proteins and growth factors.
- the medium will contain vitamin K, preferably at a concentration of about 0.1 ng/ml to about 20 ⁇ g/ml.
- Drug selection is then applied to select for the growth of cells that are expressing the selectable marker in a stable fashion.
- the drug concentration may be increased to select for an increased copy number of the cloned sequences, thereby increasing expression levels.
- Clones of stably transfected cells are then screened for expression of the desired chimeric Factor VII polypeptide.
- Suitable mammalian cell lines include the CHO (ATCC CCL 61), COS-I (ATCC CRL 1650), baby hamster kidney (BHK) and 293 (ATCC CRL 1573; Graham et al, J. Gen. Virol. 36:59-72, 1977) cell lines.
- a suitable BHK cell line is the tk.sup.-tsl3 BHK cell line (Waechter and Baserga, Proc. Natl. Acad. ScL USA 79:1106-1110, 1982), hereinafter referred to as BHK 570 cells.
- the BHK 570 cell line is available from the American Type
- a tk "ts13 BHK cell line is also available from the ATCC under accession number CRL 1632.
- a number of other cell lines may be used, including Rat Hep I (Rat hepatoma; ATCC CRL 1600), Rat Hep II (Rat hepatoma; ATCC CRL 1548), TCMK (ATCC CCL 139), Human lung (ATCC HB 8065), NCTC 1469 (ATCC CCL 9.1) and DUKX cells (Uiiaub and Chasin, Proc. Natl. Acad. Sci. USA 77:4216-4220, 1980).
- the chimeric Factor VII polypeptides of the invention may be conjugated to prolong the half-life of the polypeptide in vivo. Such conjugation may decrease renal clearance and increase the amount of Factor VII present in vivo, while decreasing the frequency of administration of the chimeric Factor VII polypeptides.
- Suitable conjugates and methods of preparing conjugated Factor VII polypeptides are described in U.S. Pat. No. 7,442,524, which is hereby incorporated by reference in its entirety.
- Transgenic animal technology may be employed to produce the chimeric Factor VII polypeptides of the invention. It is preferred to produce the proteins within the mammary glands of a host female mammal. Expression in the mammary gland and subsequent secretion of the protein of interest into the milk overcomes many difficulties encountered in isolating proteins from other sources. Milk is readily collected, available in large quantities, and biochemically well characterized. Furthermore, the major milk proteins are present in milk at high concentrations (typically from about 1 to 15 g/1). The chimeric Factor VII polypeptides of the present invention may also be produced in the urine of a host animal, which has the advantage over production in milk in that both male and female animals produce urine and that there are less proteins in urine than in milk for isolation purposes.
- milk protein genes include those genes encoding caseins (see U.S. Pat. No. 5,304,489), beta-lactoglobulin, a-lactalbumin, and whey acidic protein.
- the beta- lactoglobulin (BLG) promoter is suitable.
- a region of at least the proximal 406 bp of 5' flanking sequence of the gene will generally be used, although larger portions of the 5' flanking sequence, up to about 5 kbp, are suitable, such as about 4.25 kbp DNA segment encompassing the 5' flanking promoter and non-coding portion of the beta-lactoglobulin gene (see Whitelaw et al., Biochem. J. 286: 31-39 (1992)). Similar fragments of promoter DNA from other species are also suitable.
- a urothelium-specific promoter is used.
- a promoter that drives expression of uroplakin-related genes can be used. (See, e.g., U.S. Patent No. 6,001,646, which is hereby incorporated by reference in its entirety).
- beta-lactoglobulin gene may also be incorporated in constructs, as may genomic regions of the gene to be expressed. It is generally accepted in the art that constructs lacking introns, for example, express poorly in comparison with those that contain such DNA sequences (see Brinster et al., Proc. Natl. Acad. ScL USA 85: 836-840 (1988); Palmiter et al., Proc. Natl. Acad. ScL USA 88: 478-482 (1991); Whitelaw et al., Transgenic Res. 1: 3-13 (1991); PCT Publication No. WO 89/01343; and PCT Publication No. WO 91/02318, each of which is incorporated herein by reference).
- genomic sequences containing all or some of the native introns of a gene encoding the protein or polypeptide of interest thus the further inclusion of at least some introns from, e.g., the beta-lactoglobulin gene, is preferred.
- One such region is a DNA segment that provides for nitron splicing and RNA polyadenylation from the 3' non- coding region of the ovine beta-lactoglobulin gene. When substituted for the natural 3' non- coding sequences of a gene, this ovine beta-lactoglobulin segment can both enhance and stabilize expression levels of the protein or polypeptide of interest.
- the region surrounding the initiation ATG of the chimeric Factor VII sequence is replaced with corresponding sequences from a milk specific protein gene.
- Such replacement provides a putative tissue-specific initiation environment to enhance expression. It is convenient to replace the entire chimeric Factor VII pre-pro and 5' non-coding sequences with those of, for example, the BLG gene, although smaller regions may be replaced.
- a DNA segment encoding chimeric Factor Vila is operably linked to additional DNA segments required for its expression to produce expression units.
- additional segments include the above- mentioned promoter, as well as sequences that provide for termination of transcription and polyadenylation of mRNA.
- the expression units will further include a DNA segment encoding a secretory signal sequence operably linked to the segment encoding the chimeric Factor Vila.
- the secretory signal sequence may be a native Factor VII secretory signal sequence or may be that of another protein, such as a milk protein (see, for example, von Heijne, Nucl. Acids Res. 14: 4683-4690 (1986); and Meade et al., U.S. Pat. No. 4,873,316, which are incorporated herein by reference).
- Construction of expression units for use in transgenic animals is conveniently carried out by inserting a chimeric Factor VII sequence into a plasmid or phage vector containing the additional DNA segments, although the expression unit may be constructed by essentially any sequence of ligations. It is particularly convenient to provide a vector containing a DNA segment encoding a milk protein and to replace the coding sequence for the milk protein with that of a chimeric Factor VII polypeptide; thereby creating a gene fusion that includes the expression control sequences of the milk protein gene. In any event, cloning of the expression units in plasmids or other vectors facilitates the amplification of the chimeric Factor VII sequence. Amplification is conveniently carried out in bacterial (e.g., E.
- the vectors will typically include an origin of replication and a selectable marker functional in bacterial host cells.
- the expression unit is then introduced into fertilized eggs (including early-stage embryos) of the chosen host species.
- Introduction of heterologous DNA can be accomplished by one of several routes, including microinjection (e.g., U.S. Pat. No. 4,873,191), retroviral infection (Jaenisch, Science 240: 1468-1474 (1988)) or site- directed integration using embryonic stem (ES) cells (reviewed by Bradley et al., Bio/Technology 10: 534-539 (1992)).
- the eggs are then implanted into the oviducts or uteri of pseudopregnant females and allowed to develop to term.
- Production in transgenic plants may also be employed.
- Expression may be generalized or directed to a particular organ, such as a tuber (see, Hiatt, Nature 344:469-479 (1990); Edelbaum et al., J. Interferon Res. 12:449-453 (1992); Sijmons et al., Bio/Technology 8:217- 221 (1990); and EP 0 255 378).
- Production of the chimeric Factor VII polypeptides of the present invention may also be achieved through in vitro translation, such as for example by rabbit reticulocyte lysate, wheat germ extract and E. coli cell free systems.
- the in vitro translation may also be linked or coupled.
- Linked in vitro translation is based on transcription with a bacteriophage polymerase followed by translation in the rabbit reticulocyte lysate or wheat germ lysate systems, Coupled in vitro translation is based upon the E. coli cell free system.
- the chimeric Factor VII polypeptides of the invention are recovered from cell culture medium or milk.
- the chimeric Factor VII polypeptides of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures ⁇ e.g., preparative isoelectric focusing (IEF), differential solubility ⁇ e.g., ammonium sulfate precipitation), or extraction (see, e.g., Protein Purification, J. -C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).
- chromatography e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion
- electrophoretic procedures ⁇ e.g., preparative isoelectric focusing (IEF), differential solubility ⁇ e.g., ammonium sulfate precipitation
- extraction
- Additional purification may be achieved by conventional chemical purification means, such as high performance liquid chromatography.
- Other methods of purification including barium citrate precipitation, are known in the art, and may be applied to the purification of the novel chimeric Factor VII polypeptides described herein (see, for example, Scopes, R., Protein
- the chimeric Factor VII polypeptides of the invention are substantially pure.
- the Factor VII variants of the invention are purified to at least about 90 to 95% purity, preferably to at least about 98% purity. Purity may be assessed by e.g., gel electrophoresis, amino-terminal amino acid sequencing and reverse-phase HPLC.
- the chimeric Factor VII polypeptide is cleaved at its activation site to convert it to its two-chain form. Activation may be carried out according to procedures known in the art, such as those disclosed by Osterud, et al., Biochemistry 11:2853-2857 (1972); Thomas, U.S. Pat. No. 4,456,591; Hedner and Kisiel, /. Clin. Invest. 71:1836-1841 (1983); or Kisiel and Fujikawa, Behring Inst. Mitt. 73:29-42 (1983).
- the chimeric Factor VII polypeptide may be activated by concentrating the chimeric Factor VII polypeptide and contacting a positively charged surface or resin, for example, as described by Bjoern et al. (Research Disclosure, 269 September 1986, pp. 564-565), Factor VII may be activated by passing it through an ion-exchange chromatography column, such as Mono Q® (Pharmacia fine Chemicals) or the like.
- the chimeric Factor VII polypeptide may also be activated in solution by obtaining a solution comprising a substantially purified preparation of the chimeric Factor VII polypeptide; adding to the solution an amine compound, Ca 2+ to a final concentration of about 5mM to about 5OmM (such as about 1OmM to about 3OmM), and adjusting the final pH of the solution to about 7.2 to 8.6 (such as about 7.6 to about 8.2); incubating the resulting activation mixture at between about 2°C and about 25 0 C for an amount of time sufficient to convert at least 90% of the chimeric FVII polypeptide to chimeric FVIIa polypeptide; and, optionally, isolating the FVIIa from the activation mixture.
- the resulting activated chimeric Factor VII polypeptide may then be formulated and administered as described below.
- the chimeric Factor VII polypeptides of the invention may also be used in methods of treating bleeding disorders by way of gene therapy.
- the chimeric Factor VII polypeptides of the invention are encoded by nucleic acid molecules that may be introduced into cells of the subject by ex vivo transfer or by in vivo transfer. Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below. For general reviews of the methods of gene therapy, see Goldspiel et al., Clinical Pharmacy 1993, 12:488-505; Wu and Wu, Biotherapy 1991, 3:87-95; Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 1993, 32:573-596;
- the polynucleotides encoding the chimeric Factor VII polypeptides can be inserted into an appropriate cloning vector.
- Vectors suitable for gene therapy include viruses, such as adenoviruses, adeno-associated virus (AAV), vaccinia, herpesviruses, baculoviruses and retroviruses, parvovirus, lentivirus, bacteriophages, cosmids, plasmids, fungal vectors and other recombination vehicles typically used in the art which have been described for expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple protein expression.
- viruses such as adenoviruses, adeno-associated virus (AAV), vaccinia, herpesviruses, baculoviruses and retroviruses, parvovirus, lentivirus, bacteriophages, cosmids, plasmids, fungal vectors and other
- the vector is a viral vector.
- Viral vectors, especially adenoviral vectors can be complexed with a cationic amphiphile, such as a cationic lipid, polyL-lysine (PLL), and diethylaminoethyldextran (DELAE-dextran), which provide increased efficiency of viral infection of target cells (See, e.g., PCT Publication No. PCT/US97/21496 filed Nov. 20, 1997, incorporated herein by reference).
- Suitable viral vectors for use in the present invention include vectors derived from vaccinia, herpesvirus, AAV and retroviruses.
- a vector is used in which the coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for expression of the construct from a nucleic acid molecule that has integrated into the genome (Roller and Smithies, Proc. Natl. Acad. Sci. USA 1989, 86:8932-8935; Zijlstra et al., Nature 1989, 342:435-438; U.S. Pat. No. 6,244,113 to Zarling et al.; and U.S. Pat. No. 6,200,812 to Pati et al., each of which is incorporated herein in its entirety by reference).
- Delivery of the vector into a patient may be either direct, in which case the patient is directly exposed to the vector or a delivery complex, or indirect, in which case, cells are first transformed with the vector in vitro, and then transplanted into the patient. These two approaches are known, respectively, as in vivo and ex vivo gene therapy.
- the vector is directly administered in vivo, where it enters the cells of the subject and mediates expression of the gene.
- This can be accomplished by any of numerous methods known in the art and discussed above, e.g., by constructing it as part of an appropriate expression vector and administering it so that it becomes intracellular, e.g., by infection using a defective or attenuated retroviral or other viral vector (see, U.S. Pat. No.
- a nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation, or cationic 12-mer peptides, e.g., derived from antennapedia, that can be used to transfer therapeutic DNA into cells (Mi et al., MoI. Therapy 2000, 2:339-47).
- the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publication Nos. WO 92/06180, WO 92/22635, WO 92/20316 and WO 93/14188).
- magnetofection may be used to deliver vectors to mammals. This technique associates the vectors with superparamagnetic nanoparticles for delivery under the influence of magnetic fields. This application reduces the delivery time and enhances vector efficacy (Scherer et al., Gene Therapy 2002; 9:102-9).
- the nucleic acid can be administered using a lipid carrier.
- Lipid carriers can be associated with naked nucleic acids (e.g., plasmid DNA) to facilitate passage through cellular membranes.
- Cationic, anionic, or neutral lipids can be used for this purpose.
- cationic lipids are suitable because they have been shown to associate better with DNA which, generally, has a negative charge.
- Cationic lipids have also been shown to mediate intracellular delivery of plasmid DNA (Feigner and Ringold, Nature 1989; 337:387). Intravenous injection of cationic lipid-plasmid complexes into mice has been shown to result in expression of the DNA in lung (Brigham et al., Am. J. Med.
- cationic lipids include those disclosed, for example, in U.S. Pat. No. 5,283,185; and e.g., U.S. Pat. No. 5,767,099, the disclosures of which are incorporated herein by reference.
- the cationic lipid is N 4 -spermine cholesteryl carbamate (GL-67) disclosed in U.S. Pat. No. 5,767,099.
- Additional suitable lipids include N 4 - spermidine cholestryl carbamate (GL-53) and l-(N 4 -sperrnine)-2,3-dilaurylglycerol carbamate (GL- 89).
- an appropriate immunosuppressive treatment can be employed in conjunction with the viral vector, e.g., adenovirus vector, to avoid immuno-deactivation of the viral vector and transfected cells.
- immunosuppressive cytokines such as interleukin-12 (IL-12), interferon-. gamma. (IFN- . gamma.), or anti-CD4 antibody, can be administered to block humoral or cellular immune responses to the viral vectors.
- IL-12 interleukin-12
- IFN- . gamma. interferon-. gamma.
- anti-CD4 antibody can be administered to block humoral or cellular immune responses to the viral vectors.
- Somatic cells may be engineered ex vivo with a construct encoding a chimeric Factor VII polypeptide of the invention using any of the methods described above, and re-implanted into an individual. This method is described generally in PCT Publication No. WO 93/09222 to Selden et al. In addition, this technology is used in Cell Based Delivery's proprietary ImPACT technology, described in Payumo et al., Clin. Orthopaed. and Related Res. 2002; 403S: S228-S242.
- somatic cells e.g., fibroblasts, hepatocytes, or endothelial cells
- primary cells derived from an individual or tissue and engineered prior to passaging
- secondary cells passedaged in vitro prior to introduction in vivo
- immortalized cell lines known in the art.
- Somatic cells useful for the methods of the present invention include but are not limited to somatic cells, such as fibroblasts, keratinocytes, epithelial cells, endothelial cells, hepatocytes, formed elements of the blood, muscle cells, other somatic cells that can be cultured, and somatic cell precursors.
- the cells are hepatocytes.
- Constructs that include the polynucleotide encoding the chimeric FVIIa polypeptides of the invention and, optionally, nucleic acids encoding a selectable marker, along with additional sequences necessary for expression of the chimeric FVIIa in recipient primary or secondary cells, are used to transfect primary or secondary cells in which the encoded product is to be produced.
- Such constructs include but are not limited to infectious vectors, such as retroviral, heipes, adenovirus, adeno-associated virus, mumps and poliovirus vectors, can be used for this purpose.
- Transdermal delivery is especially suited for indirect transfer using cell types of the epidermis including keratinocytes, melanocytes, and dendritic cells (Pfutzner et al., Expert Opin. Investig. Drugs 2000; 9:2069-83).
- the vector for gene therapy is a single-stranded self complementary adeno-associated virus.
- this self complementary adeno-associated virus may contain the small transhyretin promoter-enhancer, introns from the mouse minute virus and the polyadenylation signal from bovine growth hormone.
- the vector may also contain the RKRRKR sequence described by Margaritis et al. that causes the Factor VII to be secreted in the active form, i.e., Factor Vila. (Margaritis et al., J. CUn. Invest., 2004; 113:1025-31).
- the chimeric Factor VII polypeptides according to the present invention may be used to control bleeding disorders which have several causes such as clotting factor deficiencies (e.g., hemophilia A and B or deficiency of coagulation factors XI or VII) or clotting factor inhibitors, or they may be used to control excessive bleeding occurring in subjects with a normally functioning blood clotting cascade (no clotting factor deficiencies or inhibitors against any of the coagulation factors).
- the bleedings may be caused by a defective platelet function, thrombocytopenia or von Willebrand's disease. They may also be seen in subjects in whom an increased fibrinolytic activity has been induced by various stimuli.
- the haemostatic mechanism may be overwhelmed by the demand of immediate hemostasis and they may develop bleedings in spite of a normal haemostatic mechanism. Achieving satisfactory hemostasis is also a problem when bleedings occur in organs such as the brain, inner ear region and eyes and may also be a problem in cases of diffuse bleedings (hemorrhagic gastritis and profuse uterine bleeding) when it is difficult to identify the source. The same problem may arise in the process of taking biopsies from various organs (liver, lung, tumor tissue, gastrointestinal tract) as well as in laparoscopic surgery. These situations share the difficulty of providing hemostasis by surgical techniques (sutures, clips, etc.).
- Acute and profuse bleedings may also occur in subjects on anticoagulant therapy in whom a defective hemostasis has been induced by the therapy given. Such subjects may need surgical interventions in case the anticoagulant effect has to be counteracted rapidly. Another situation that may cause problems in the case of unsatisfactory hemostasis is when subjects with a normal haemostatic mechanism are given anticoagulant therapy to prevent thromboembolic disease.
- anticoagulant therapy may include heparin, other forms of proteoglycans, warfarin or other forms of vitamin K-antagonists as well as aspirin and other platelet aggregation inhibitors.
- the chimeric Factor VII polypeptides of the invention will typically be administered within about 24 hours prior to performing the intervention, and for as much as 7 days or more thereafter. Administration as a coagulant can be by a variety of routes as described herein.
- the dose of the chimeric Factor VII polypeptides ranges from about 0.05 mg/day to about 500 mg/day, preferably from about 1 mg/day to about 200 mg/day, and more preferably from about 10 mg/day to about 175 mg/day for a 70 kg subject as loading and maintenance doses, depending on the weight of the subject and the severity of the condition.
- One of skill in the art would be able to determine the optimal dose for a given subject and a given condition.
- the pharmaceutical compositions are primarily intended for parenteral administration for prophylactic and/or therapeutic treatment.
- the pharmaceutical compositions are administered parenterally, i.e., intravenously, subcutaneously, or intramuscularly, or it may be administered by continuous or pulsatile infusion.
- the pharmaceutical compositions may be formulated for administration in various ways, including, but not limited to, orally, subcutaneously, intravenously, intracerebrally, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, intraocularly, or in any other acceptable manner.
- compositions for parenteral administration comprise the chimeric Factor VII polypeptide of the invention in combination with, preferably dissolved in, a pharmaceutically acceptable carrier, preferably an aqueous carrier.
- a pharmaceutically acceptable carrier preferably an aqueous carrier.
- aqueous carriers such as water, buffered water, 0.4% saline, 0.3% glycine and the like.
- the chimeric Factor VII polypeptides of the invention may also be formulated with compositions that prolong stability and storage, such as methionine and sucrose.
- the chimeric Factor VII polypeptides of the invention can also be formulated into liposome preparations for delivery or targeting to the sites of injury. Liposome preparations are generally described in, e.g., U.S. Pat. Nos.
- compositions may be sterilized by conventional, well-known sterilization techniques.
- the resulting aqueous solutions may be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration.
- the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc.
- the compositions may also contain preservatives, isotonifiers, non- ionic surfactants or detergents, antioxidants and/or other miscellaneous additives.
- chimeric Factor VII polypeptide concentration in these formulations can vary widely, i.e., from less than about 0.5% by weight, usually at or at least about 1% by weight to as much as about 15 or 20% by weight and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.
- a typical pharmaceutical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution and 10 mg of the chimeric Factor VII polypeptide.
- Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in, for example, Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Company, Easton, Pa. (1990).
- compositions containing the chimeric Factor VII polypeptide of the present invention can be administered for prophylactic and/or therapeutic treatments.
- compositions are administered to a subject already suffering from a disease, as described above, in an amount sufficient to cure, alleviate or partially arrest the disease and its complications.
- An amount adequate to accomplish this is defined as a "therapeutically effective amount.”
- amounts effective for this purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject.
- the effective amount will range from about 0.05 mg up to about 500 mg of the chimeric Factor VII polypeptide per day for a 70 kg subject, with dosages of from about 1.0 mg to about 200 mg of the chimeric Factor VII polypeptide per day being more commonly used.
- compositions containing the chimeric Factor VII polypeptide of the invention are administered to a subject susceptible to or otherwise at risk of a disease state or injury to enhance the subject's own coagulative capability.
- prophylactically effective dose Such an amount is defined to be a “prophylactically effective dose.”
- prophylactic applications the precise amounts once again depend on the subject's state of health and weight, but the dose generally ranges from about 0.05 mg to about 500 mg per day for a 70-kilogram subject, more commonly from about 1.0 mg to about 200 mg per day for a 70-kilogram subject.
- compositions can be carried out with dose levels and patterns being selected by the treating physician.
- the chimeric Factor VII polypeptides may be administered by continuous infusion using e.g., a portable pump system.
- the chimeric Factor VII polypeptides of the present invention may also be formulated in sustained, or extended release formulations.
- sustained, or extended release compositions include, but are not limited to, semi- permeable matrices of solid hydrophobic particles containing the polypeptide.
- Local delivery of the chimeric Factor Vila polypeptides of the present invention may be carried out, for example, by means of a spray, perfusion, double balloon catheters, stent, incorporated into vascular grafts or stents, hydrogels used to coat balloon catheters, or other well established methods, hi any event, the pharmaceutical compositions should provide a quantity of Factor VII variant sufficient to effectively treat the subject.
- Sacl site is at the junction of the EGF-I and EGF-2 domains (residues 82-83 of Factor VII; residues 83-84 of Factor IX);
- Notl site is at the 3' end of the EGF-2 domain (residues 135-137 of Factor VII; residues 132-134 of Factor IX.
- Various chimeras were constructed using these restriction sites to exchange domains between Factor VII and Factor IX and are depicted in FIG. 1. The same, or similar restriction sites can be used to exchange domains between Factor VII and Protein S.
- the amino acid sequence of the resulting chimeras are set forth in SEQ ID NO:1 (Factor IX signal, propeptide, GLA and EGFl domains, with Factor VII EGF2 and catalytic domains) and SEQ ID NO:2 (Factor IX signal and propeptide domains, Protein S GLA domain, Factor IX EGFl domain, with Factor VII EGF2 and catalytic domains).
- SEQ ID NO:1 Vector IX signal, propeptide, GLA and EGFl domains, with Factor VII EGF2 and catalytic domains
- SEQ ID NO:2 Vector IX signal and propeptide domains, Protein S GLA domain, Factor IX EGFl domain, with Factor VII EGF2 and catalytic domains.
- the resulting recombinant constructs were then co-transfected with pSV2neo and pCMVhGC into the 293 human kidney cell line (ATCC CRL 1573).
- a clone expressing a high level of each construct was selected and screened as previously described (Toomey et al, 1991, J. Biol. Chem., 266:19198-19202).
- Each screened clone was expanded to 900 cm 2 roller bottles for large scale production and recombinant proteins were purified by a pseudo- affinity chromatographic method using Fast Flow Q-Sepharose and elution with a calcium gradient, followed by a NaCl gradient.
- the thrombin generation of Factor Vila was determined using an in vitro model of hemophilia. Monocytes were used as a source of tissue factor and combined with unactivated platelets and synthetic plasma containing plasma concentrations of Factors V, VII, IX, VIII, and XI, and plasma concentrations of antithrombin and TFPI. Hemophilic conditions were created by omitting factors VIII and IX.
- Monocytes were prepared by drawing 4ml of blood from a healthy individual and placing in a sodium citrate tube. The blood was carefully layered on top of 3 ml of Accu- PrepTM Lymphocyte separation medium (Accurate Chemicals, NY, USA) in a 15ml conical tube and centrifuged at 1500 rpm for 30 minutes. The mononuclear layer was then removed and added to an equal volume of Versene (Lineberger Tissue Culture) at 4 0 C and centrifuged at 800 rpm for 10 minutes. The resulting pellet was resuspended in 5ml of Versene at 4 0 C and centrifuged at 800 rpm for 10 minutes.
- Versene Lineberger Tissue Culture
- the resulting pellet was resuspended in 4ml of macrophage SFM media (Life Technologies, CA, USA), supplemented with 500ng/ml of lipopolysaccharide (LPS) (Sigma-Aldrich, MO, USA) and cells were plated at 200 ⁇ l/well of a 96-well plate. The plate was incubated at 37 0 C, 5% CO 2 for two hours and then washed three times with macrophage SFM media and then incubated overnight.
- LPS lipopolysaccharide
- Platelets were prepared by drawing 4ml of blood from a healthy individual and placing in a sodium citrate tube. The blood was carefully layered on top of 5ml of Accu-
- PrepTM Lymphocyte separation medium (Accurate Chemicals, NY, USA) in a 15ml conical tube and centrifuged at 1500 rpm for 30 minutes. The platelet layer was then removed and added to an equal volume of citrate-glucose-saline with 10 ⁇ g/ml of prostaglandin Ei (PGEl)
- Synthetic plasma for the in vitro assay that mimics hemophilia was generated by using Factor XI C-I -esterase inhibitor at a concentration of 5 ⁇ g/ml with the addition after 1 hour incubation with the previously prepared monocytes of 200 ⁇ g/ml antithrombin, 0.07 ⁇ g/ml of TFPI, 100mg/ml of prothrombin, 8 ⁇ g/ml of Factor X and 0.5 ⁇ g/ml of Factor VII.
- Factor V was added at a concentration of 7 ⁇ g/ml.
- Factor IX was added after the 1 hour incubation at a concentration of 4 ⁇ g/ml and following the overnight incubation, Factor VIII was added at lU/ml.
- 260 ⁇ l of platelets were added to the above synthetic plasma solutions and the resulting suspension was added to the monocytes to start the reaction. At timed intervals 10 ⁇ l samples were removed and added to 90 ⁇ l of thrombin assay buffer containing ImM
- Thrombin concentration was determined using the following formula:
- [thrombin] dilution x ((A405-background)/(stop-start))/(conversion factor) wherein the conversion factor is InM thrombin gives a rate of 0.0117 OD/min at 405nm.
- Thrombin generation in normal conditions shows peak thrombin production with a short lag phase (FIG. 2).
- Increasing concentrations of wild-type Factor Vila improved thrombin production in the hemophilic condition.
- FIG. T Example III - Thrombin generation of chimeric Factor Vila polypeptides
- Example II The thrombin generation of the chimeric proteins produced in Example I was determined using an in vitro model of hemophilia described in Example II.
- 1OnM of a chimeric Factor Vila containing the EGF-2 and catalytic domains of Factor VII and the GLA and EGF-I domains of Factor IX, or a chimeric Factor Vila containing the GLA, EGF-2 and catalytic domains of Factor VII and the EGF-I domain of Factor IX had a similar activity to 5OnM of wild-type Factor Vila. (FIG. 3). Looking at peak thrombin production in relation to the control, neither wild-type
- the clotting activity of the chimeric Factor Vila polypeptides was assessed in vivo, in a clotting assay, as described by Buyue, Y., et al, 2008, Blood, 112:3234-3241. Briefly, Factor VII was administered to a hemophilia B mouse (2mg/kg of NovoSeven®, 2mg/kg of a chimeric Factor Vila containing the GLA and EGF-I domains of Factor IX and the EGF-2 and catalytic domains of Factor Vila, or 1.4mg/kg of a chimeric Factor Vila containing the GLA domain of Protein S, the EGF-I domain of Factor IX and the EGF-2 and catalytic domains of Factor Vila), through a catheter inserted into a vein in the leg.
- mice were anesthetized and the saphenous vein of the other leg was transected by pushing a small gauge needle through it. The distal portion is then cut by inserting the tip of a pair of scissors into the vein and snipping to create a small cup. A clot is formed and the time until bleeding stops was recorded. The clot was then removed using a 30 gauge needle and the time until bleeding stops was again recorded. This process was repeated for 30 minutes. The number of clots was recorded as the number of disruptions. The times recorded were averaged and recorded as an average time.
- the experiment was conducted on one mouse for the wild-type mouse and the chimeric FactorVIIa containing the GLA domain of Protein S, the EGF-I domain of Factor IX and the EGF-2 and catalytic domains of Factor Vila.
- the experiment was conducted on two hemophilia B mice with the same results.
- the hemophilia B mouse that was not administered any Factor VII, the 0.25 disruptions recorded in Table 1 below indicate that only one out of four mice did not bleed out with the initial injury. Table 1.
- the experiment was repeated with one hemophilia B mouse with no treatment, one hemophilia B mouse administered 2mg/kg of NovoSeven®, one hemophilia B mouse administered 2mg/kg of a chimeric Factor Vila containing the GLA and EGF-I domains of Factor IX and the EGF-2 and catalytic domains of Factor Vila and one wild-type mouse with no treatment.
- the hemophilia B mouse administered the 2mg/kg of chimeric Factor Vila containing the GLA and EGF-I domains of Factor IX and the EGF-2 and catalytic domains of Factor Vila had a shorter average time to cessation of bleeding than the hemophilia B mouse administered 2mg/kg of NovoSeven® and the wild-type mouse. (FIG. 5).
- Thrombogenicity of the chimeric Factor Vila polypeptides of the invention can be tested in a mouse model that expresses high levels of these proteins. Recently, it has been shown that 50% of mice expressing greater than 2 ⁇ g/ml recombinant wild type mouse factor Vila died from thromboses within 16 months. Hemophilia B mice expressing similar levels of factor Vila had the same mortality rates and that when the mice were back-crossed into the C57BL/6J mouse strain, thromboses occurred much earlier ( ⁇ 4 months). (Aljamali MN, et al. / Clin Invest. 2008;118:1825-1834).
- a hemophilia B mouse (strain C57BL/6J) expressing 2-10 ⁇ g or more of the chimeric polypeptides can be produced and if expression of the chimeric Factor VII polypeptides cause thromboses then these mice should develop them early on ( ⁇ 4 months).
- the mouse strain can be developed by using a new self complementary adeno associated vector (AAV) developed by Dr. Paul Monahan of the Gene Therapy Center at UNC. (Wu Z, et al. MoI Ther. 2008;16:280-289).
- AAV self complementary adeno associated vector
- This vector contains the small transhyretin promoter-enhancer (TTR promoter), introns from the minute virus of mouse, the MVM and the bovine growth hormone pA signal. It has been shown that injection of 1 x l ⁇ ' ' vector genomes, based on this vector, into the portal vein resulted in sustained expression of Factor IX of 7 ⁇ g per ml within 8 weeks of infection. (Wu Z, et al. MoI Ther. 2008; 16:280- 289).
- the cDNA of both mouse and human factor Vila, as well as the chimeric Factor VII polypeptides of the invention may be used to assess thrombogenicity.
- mouse polypeptides can be generated. It has been reported that mouse tissue factor does not react with human Factor VII, so mouse polypeptides are used to demonstrate that tissue factor is irrelevant to the action of administered Factor Vila in trauma but is related to thrombosis.
- the mouse polypeptides that can be used to test this hypothesis include a wild-type mouse Factor VII (SEQ ID NO: 3), a wild-type mouse Factor VII with an RKRRKR sequence to cause the polypeptide to be secreted in the two-chain, active form (FVIIa) (SEQ ID NO:4), a mouse Factor IX signal, propeptide, GLA and EGFl domains, with Factor VII EGF2 and catalytic domains and an RKRRKR sequence (SEQ ID NO: 5) and a mouse Factor IX signal and propeptide domains, Protein S GLA domain, Factor IX EGFl domain, with Factor VII EGF2 and catalytic domains and an RKRRKR sequence (SEQ ID NO: 6).
- the chimeric mouse Factor VII polypeptides (SEQ ID NOS: 5 and 6) will have a reduced affinity for tissue factor (perhaps by as much as 100 fold lower when compared to the wild-type FVII molecule) and this should be sufficient to prevent unwanted thromboses.
- the chimeric Factor VII polypeptides may also be additionally modified to further reduce the affinity for tissue factor.
- An example of such a mutation is to change the methionine at residue 306 to alanine.
- Other modifications of the chimeric Factor VII polypeptides may be included that result in a higher specific activity of Factor Vila. Examples of such modifications include the following equivalent to residues 158, 296 and 298 of the human sequence: V158D, E296V and M298Q.
- the wild-type and chimeric mouse Factor VII polypeptides described above can be constructed by using mouse Factor VII cDNA as a template and using oligonucleotide primers to amplify the various domains and then inserting the constructs into a pSC-TTR- mvm vector, the construction of which is described in Wu et al., Molecular Therapy, 2008; 16:280-289.
- the wild-type mouse Factor VII can be amplified from mouse Factor VII cDNA using the following primers: 5'- TGAGGATCCCCACCATGGTTCCACAGGCGCATGGGCT -3' (SEQ ID NO:7) and 5'- TTCCCCAGCATGCCTACAGTAGTGGGAGTCGGAAAAC-3' (SEQ ID NO: 8).
- the amplified fragment can then be digested with BamHI/Sphl and inserted into the pSC-TTR- mvm vector between the Bglll/Sphl sites. Subsequently, the BGH polyadenylation sequence can be inserted into the resulting vector at the Sphl site.
- the wild-type mouse Factor VII construct with the RKRRKR sequence can be constructed in a similar fashion. Specifically, the wild-type mouse Factor VII with the RKRRKR sequence can be amplified from mouse Factor VII cDNA using the following primers: 5'- TGAGGATCCCCACCATGGTTCCACAGGCGCATGGGCT -3' (SEQ ID NO: 1
- the resulting amplified fragment can then be digested with BamHI/Sphl and inserted into the pSC-TTR-mvm vector between the Bglll/Sphl sites. Subsequently, the BGH polyadenylation sequence can be inserted into the resulting vector at the Sphl site.
- the construct containing the mouse Factor IX signal, propeptide, GLA and EGFl domains, with Factor VII EGF2 and catalytic domains and an RKRRKR sequence is similarly constructed. Specifically, a first fragment is generated using mouse FactoiTX cDNA as a template and the following primers:
- a second fragment is generated using mouse Factor VII as a template and the following primers:
- a third fragment can be generated using mouse Factor VII as a template and the following primers : 5 ' -TTCCCCAGCATGCCTACAGTAGTGGGAGTCGGAAAAC-S ' (SEQ ID NO: 8) and
- the resulting amplified fragment is then digested with BamHI/Sphl and inserted into the pSC-TTR-mvm vector between the Bglll/Sphl sites. Subsequently, the BGH polyadenylation sequence is inserted into the resulting vector at the Sphl site.
- a similar process can be used to generate the construct containing the mouse Factor IX signal and propeptide domains, Protein S GLA domain, Factor IX EGFl domain, with Factor VII EGF2 and catalytic domains and an RKRRKR sequence (SEQ ID NO: 6).
- a first fragment can be generated using mouse Factor IX cDNA and the following primers: 5'- AGGCCTGAAG ATCTCCACC ATGA AGC ACCTGA AC ACCGTC- 3' (SEQ ID NO: 11) and
- a second fragment can be generated using mouse Protein S as a template and the following primers:
- a third fragment can be generated using the vector with the mouse Factor IX signal, propeptide, GLA and EGFl domains, with Factor VII EGF2 and catalytic domains and an RKRRKR sequence as a template and the following primers:
- the resulting amplified fragment is then digested with BamHI/Sphl and inserted into the pSC-TTR-mvm vector between the Bglll/Sphl sites. Subsequently, the BGH polyadenylation sequence can be inserted into the resulting vector at the Sphl site.
- the wild-type mouse Factor VII (SEQ ID NO:3) and wild-type mouse Factor VII with the RKRRKR sequence (SEQ ID NO:4) vector constructs were each injected into two male hemophilia B mice of matched age (5X10 11 vector genomes per mouse).
- mice The mouse Factor IX signal, propeptide, GLA and EGFl domains, with Factor VII EGF2 and catalytic domains and an RKRRKR sequence (SEQ ID NO:5) and mouse Factor IX signal and propeptide domains, Protein S GLA domain, Factor IX EGFl domain, with Factor VII EGF2 and catalytic domains and an RKRRKR sequence (SEQ ID NO: 6) vector constructs were each injected into three male hemophilia B mice of matched age (5X10 11 vector genomes per mouse). Approximately three weeks post- injection, all mice injected with either wild-type mouse Factor VII (SEQ ID NO:3) or wild-type mouse Factor VII with the RKRRKR sequence (SEQ ID NO:4) died.
- mice injected with either mouse Factor IX signal, propeptide, GLA and EGFl domains, with Factor VII EGF2 and catalytic domains and an RKRRKR sequence (SEQ ID NO:5), or mouse Factor IX signal and propeptide domains, Protein S GLA domain, Factor IX EGFl domain, with Factor VII EGF2 and catalytic domains and an RKRRKR sequence (SEQ ID NO:6) were alive and showed no adverse symptoms approximately five weeks post- injection.
- Blood is collected once a week from the mice and after six to eight weeks following injection the level of mouse Factor VII polypeptide can be measured.
- antigen levels to the mouse Factor VII polypeptides can be determined indirectly by measuring the clotting activity in vitro from blood samples of the injected mice (Margaritas et al, Gene Therapy 2009; 113:3682-3689).
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Power Engineering (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Computer Hardware Design (AREA)
- General Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Ceramic Engineering (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Manufacturing & Machinery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2012102422/15A RU2563231C2 (en) | 2009-06-25 | 2010-06-25 | Factor vii chimeric molecules |
BRPI1011244A BRPI1011244A2 (en) | 2009-06-25 | 2010-06-25 | method for treating a bleeding disorder in an individual, chimeric coagulation protein, nucleic acid molecule, vector, and, cell |
ES10792705.5T ES2524974T3 (en) | 2009-06-25 | 2010-06-25 | Chimeric Factor VII molecules |
CN201080038640.1A CN102596231B (en) | 2009-06-25 | 2010-06-25 | Chimeric factor VII molecules |
JP2012517759A JP5909180B2 (en) | 2009-06-25 | 2010-06-25 | Chimeric factor VII molecule |
EP10792705.5A EP2445513B1 (en) | 2009-06-25 | 2010-06-25 | Chimeric factor vii molecules |
CA2764758A CA2764758C (en) | 2009-06-25 | 2010-06-25 | Chimeric factor vii molecules |
AU2010266065A AU2010266065B2 (en) | 2009-06-25 | 2010-06-25 | Chimeric Factor VII molecules |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22027809P | 2009-06-25 | 2009-06-25 | |
US61/220,278 | 2009-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010151736A1 true WO2010151736A1 (en) | 2010-12-29 |
Family
ID=43381016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/039934 WO2010151736A1 (en) | 2009-06-25 | 2010-06-25 | Chimeric factor vii molecules |
Country Status (10)
Country | Link |
---|---|
US (3) | US8647620B2 (en) |
EP (1) | EP2445513B1 (en) |
JP (1) | JP5909180B2 (en) |
CN (1) | CN102596231B (en) |
AU (1) | AU2010266065B2 (en) |
BR (1) | BRPI1011244A2 (en) |
CA (1) | CA2764758C (en) |
ES (1) | ES2524974T3 (en) |
RU (1) | RU2563231C2 (en) |
WO (1) | WO2010151736A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130216513A1 (en) * | 2010-07-09 | 2013-08-22 | Biogen Idec Hemophilia Inc. | Chimeric Clotting Factors |
WO2014151535A1 (en) * | 2013-03-15 | 2014-09-25 | Bayer Healthcare Llc | Gla domains as targeting agents |
WO2014190860A1 (en) * | 2013-05-29 | 2014-12-04 | 四川大学 | Human source egf structural domain protein and application of same |
JP2016500519A (en) * | 2012-10-26 | 2016-01-14 | フリーイェ・ユニヴェルシテイト・ブリュッセルVrije Universieit Brussel | Vectors and methods and uses for liver-directed gene therapy for hemophilia |
US9982248B2 (en) | 2008-09-15 | 2018-05-29 | Uniqure Biopharma B.V. | Factor IX polypeptide mutant, its uses and method for its production |
US10398787B2 (en) | 2012-10-26 | 2019-09-03 | Vrije Universiteit Brussel | Vectors for liver-directed gene therapy of hemophilia and methods and use thereof |
CN110707150A (en) * | 2019-11-13 | 2020-01-17 | 中国电子科技集团公司第十三研究所 | double-T-shaped nano gate and preparation method thereof |
US11168125B2 (en) | 2003-05-06 | 2021-11-09 | Bioverativ Therapeutics Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
US11981723B2 (en) | 2017-09-05 | 2024-05-14 | GLAdiator Biosciences, Inc. | Method of targeting exosomes |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100016462A (en) * | 2007-04-13 | 2010-02-12 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | Modified factor vii polypeptides and uses thereof |
TWI538916B (en) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | Factor vii polypeptides that are modified and uses thereof |
EP2445513B1 (en) | 2009-06-25 | 2014-08-27 | The University of North Carolina At Chapel Hill | Chimeric factor vii molecules |
TWI595004B (en) | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | Modified factor ix polypeptides and uses thereof |
WO2012149463A1 (en) * | 2011-04-29 | 2012-11-01 | The University Of North Carolina At Chapel Hill | Chimeric factor vii molecules with enhanced half life and methods of use |
JP2015525222A (en) * | 2012-06-08 | 2015-09-03 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Chimeric coagulation factor |
EP4079316A1 (en) | 2012-06-08 | 2022-10-26 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
SG11201505926VA (en) | 2013-03-15 | 2015-09-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
EP3830273A4 (en) | 2018-08-03 | 2022-05-18 | Duke University | Protein c-factor vii chimeras |
US20210069306A1 (en) | 2019-08-15 | 2021-03-11 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090093410A1 (en) * | 2006-03-16 | 2009-04-09 | Lars Otto Uttenthal | Methods for Local Treatment with Factor VII |
US20090098103A1 (en) * | 2007-04-13 | 2009-04-16 | Madison Edwin L | Modified factor VII polypeptides and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235638B2 (en) | 2001-03-22 | 2007-06-26 | Novo Nordisk Healthcare A/G | Coagulation factor VII derivatives |
CA2528239A1 (en) * | 2003-06-05 | 2004-12-16 | Canadian Blood Services | Mutants of the factor vii epidermal growth factor domain |
ES2315664T3 (en) | 2003-06-30 | 2009-04-01 | Domantis Limited | SINGLE-DOMAIN ANTIBODIES (DAB) PEGILATED. |
TW200804416A (en) | 2006-06-19 | 2008-01-16 | Nautilus Technology Llc | Modified coagulation factor IX polypeptides and use thereof for treatment |
WO2008145139A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Fusion or linked proteins with extended half life |
TWI538916B (en) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | Factor vii polypeptides that are modified and uses thereof |
EP2445513B1 (en) | 2009-06-25 | 2014-08-27 | The University of North Carolina At Chapel Hill | Chimeric factor vii molecules |
-
2010
- 2010-06-25 EP EP10792705.5A patent/EP2445513B1/en not_active Not-in-force
- 2010-06-25 CA CA2764758A patent/CA2764758C/en not_active Expired - Fee Related
- 2010-06-25 US US12/823,382 patent/US8647620B2/en active Active
- 2010-06-25 JP JP2012517759A patent/JP5909180B2/en active Active
- 2010-06-25 CN CN201080038640.1A patent/CN102596231B/en not_active Expired - Fee Related
- 2010-06-25 WO PCT/US2010/039934 patent/WO2010151736A1/en active Application Filing
- 2010-06-25 RU RU2012102422/15A patent/RU2563231C2/en not_active IP Right Cessation
- 2010-06-25 ES ES10792705.5T patent/ES2524974T3/en active Active
- 2010-06-25 BR BRPI1011244A patent/BRPI1011244A2/en not_active Application Discontinuation
- 2010-06-25 AU AU2010266065A patent/AU2010266065B2/en not_active Ceased
-
2011
- 2011-04-29 US US13/097,609 patent/US20120064075A1/en not_active Abandoned
-
2014
- 2014-02-10 US US14/176,330 patent/US9238060B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090093410A1 (en) * | 2006-03-16 | 2009-04-09 | Lars Otto Uttenthal | Methods for Local Treatment with Factor VII |
US20090098103A1 (en) * | 2007-04-13 | 2009-04-16 | Madison Edwin L | Modified factor VII polypeptides and uses thereof |
Non-Patent Citations (3)
Title |
---|
JIN J. ET AL: "Factor VIIa's First epidermal growth factor-like domain's role in catalytic activity", BIOCHEMISTRY, vol. 38, 1999, pages 1185 - 1192, XP008150202 * |
MELTON L. G. ET AL: "Location of the platelet binding site in zymogen coagulation factor IX", BLOOD COAGULATION AND FIBRINOLYSIS, vol. 12, 2001, pages 237 - 243, XP008056235 * |
See also references of EP2445513A4 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11168125B2 (en) | 2003-05-06 | 2021-11-09 | Bioverativ Therapeutics Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
US9982248B2 (en) | 2008-09-15 | 2018-05-29 | Uniqure Biopharma B.V. | Factor IX polypeptide mutant, its uses and method for its production |
US10465180B2 (en) | 2008-09-15 | 2019-11-05 | Uniqure Biopharma B.V. | Factor IX polypeptide mutant, its uses and method for its production |
AU2011274423B2 (en) * | 2010-07-09 | 2016-02-11 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
US10927362B2 (en) | 2010-07-09 | 2021-02-23 | Bioverativ Therapeutics Inc. | Processable single chain molecules and polypeptides made using same |
US9856468B2 (en) | 2010-07-09 | 2018-01-02 | Bioverativ Therapeutics Inc. | Processable single chain molecules and polypeptides made using same |
US10968442B2 (en) | 2010-07-09 | 2021-04-06 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
US20130216513A1 (en) * | 2010-07-09 | 2013-08-22 | Biogen Idec Hemophilia Inc. | Chimeric Clotting Factors |
US10398787B2 (en) | 2012-10-26 | 2019-09-03 | Vrije Universiteit Brussel | Vectors for liver-directed gene therapy of hemophilia and methods and use thereof |
JP2016500519A (en) * | 2012-10-26 | 2016-01-14 | フリーイェ・ユニヴェルシテイト・ブリュッセルVrije Universieit Brussel | Vectors and methods and uses for liver-directed gene therapy for hemophilia |
US11419950B2 (en) | 2012-10-26 | 2022-08-23 | Vrije Universiteit Brussel | Vectors for liver-directed gene therapy of hemophilia and methods and use thereof |
RU2711091C2 (en) * | 2013-03-15 | 2020-01-15 | Гладиатор Байосайенсиз, Инк. | Gla domains as targeting agents |
US10894075B2 (en) | 2013-03-15 | 2021-01-19 | GLAdiator Biosciences, Inc. | Gla domains as targeting agents |
WO2014151535A1 (en) * | 2013-03-15 | 2014-09-25 | Bayer Healthcare Llc | Gla domains as targeting agents |
WO2014190860A1 (en) * | 2013-05-29 | 2014-12-04 | 四川大学 | Human source egf structural domain protein and application of same |
US11981723B2 (en) | 2017-09-05 | 2024-05-14 | GLAdiator Biosciences, Inc. | Method of targeting exosomes |
CN110707150A (en) * | 2019-11-13 | 2020-01-17 | 中国电子科技集团公司第十三研究所 | double-T-shaped nano gate and preparation method thereof |
CN110707150B (en) * | 2019-11-13 | 2023-06-27 | 中国电子科技集团公司第十三研究所 | double-T-shaped nano gate and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
AU2010266065B2 (en) | 2016-01-14 |
US8647620B2 (en) | 2014-02-11 |
RU2563231C2 (en) | 2015-09-20 |
US20100330059A1 (en) | 2010-12-30 |
JP2012531206A (en) | 2012-12-10 |
AU2010266065A1 (en) | 2012-02-09 |
CA2764758C (en) | 2019-02-12 |
CA2764758A1 (en) | 2010-12-29 |
US9238060B2 (en) | 2016-01-19 |
EP2445513A1 (en) | 2012-05-02 |
CN102596231A (en) | 2012-07-18 |
ES2524974T3 (en) | 2014-12-16 |
CN102596231B (en) | 2016-01-20 |
EP2445513B1 (en) | 2014-08-27 |
JP5909180B2 (en) | 2016-04-26 |
US20140302005A1 (en) | 2014-10-09 |
RU2012102422A (en) | 2013-07-27 |
EP2445513A4 (en) | 2013-01-16 |
BRPI1011244A2 (en) | 2016-03-22 |
US20120064075A1 (en) | 2012-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9238060B2 (en) | Chimeric factor VII molecules | |
EP2226385B1 (en) | Human Coagulation Factor VII Variants | |
US7416860B2 (en) | Nucleic acids encoding human coagulation factor VII variants | |
EP1282693B1 (en) | Human coagulation factor vii variants | |
US7695935B2 (en) | Nucleic acids encoding human coagulation FVII polypeptides | |
AU2001287550A1 (en) | Human coagulation factor VII variants | |
AU2008261165A1 (en) | Human coagulation factor VII variants | |
WO2012149463A1 (en) | Chimeric factor vii molecules with enhanced half life and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080038640.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10792705 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2764758 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012517759 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 606/CHENP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010792705 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010266065 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012102422 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2010266065 Country of ref document: AU Date of ref document: 20100625 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1011244 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1011244 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111220 |